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ABSTRACT 
 Cancer has been thought of as a mostly genetic phenomenon, however recent research 
into epigenetic causes of cancer emphasizes that these causes of cancer are also important.  RIZ1 
is a tumor suppressor which is silenced in many human leukemias, such as human Acute 
Myeloid Leukemia and Chronic Myelogenous Leukemia.  It was the goal of this thesis to re-
express RIZ1 using three epigenetic drugs: decitabine, a DNA methylation inhibitor, Trichostatin 
A, a histone deacetylase inhibitor and chaetocin, an inhibitor of SUV39h1.  Cells were treated 
with these drugs and analyzed for toxicity, methylation status, and RIZ1 expression levels.  The 
synergy between the drugs was also determined.  It was found that cells treated with decitabine 
and chaetocin had an induction of RIZ1 expression.  Chaetocin induced RIZ1 expression without 
affecting the methylation status of the cell.  Also, cells which were treated with decitabine paired 
with either Trichostatin A or chaetocin showed the highest amount of RIZ1 expression.  Cells 
treated with all three drugs together had a higher amount of RIZ1 expression than cells treated 
with either drug alone, however had less expression than cells which had been treated with 
decitabine paired with either Trichostatin A or chaetocin. Using these data a model was 
developed in which H3K9 methylation is the dominant epigenetic event in transcriptional 
silencing. 
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1.  REVIEW OF THE LITERATURE 
1.1  Introduction 
Cancer is a genetic disease, and so determining the genetic causes of cancer is currently a 
common topic of research.  Chromosomal translocations such as the translocation which creates 
the BCR-ABL oncogene are at the forefront of this research.  Genetic causes of cancer are not 
the only source of cancer that is being investigated; epigenetic mechanisms also play an 
important role in the appearance and progression of cancers (Iacobuzio-Donahue, 2008). 
Epigenetics involves the study of heritable changes in gene function that do not involve 
changes to the DNA code; epigenetics literally means “above” the genes.  Two important 
developments in cancer biology occurred as the result of the discovery of epigenetic gene 
regulation.  The first discovery is that gene regulation is a means by which cancer appears and 
progresses, and the second is that new treatments can be developed based on epigenetic 
mechanisms.  An example of this is that the epigenetic drugs decitabine and vorinostat, a DNA 
methylation inhibitor and histone deacetylase inhibitor respectively, have been approved for 
treatment of specific tumors (Esteller, 2008).   
The general goal of this thesis was to explore the epigenetic gene regulation of tumor 
suppressor genes involved in human Chronic Myelogenous Leukemia (CML) and Acute 
Myeloid Leukemia (AML), and to explore the relationship between DNA methylation, histone 
acetylation and histone methylation using small molecule inhibitors.  The literature review aims 
to familiarize the reader with CML and AML, RIZ1, epigenetic mechanisms in general, and 
some pharmaceuticals that are showing great promise in the field of cancer.  Emphasis will be 
placed on aberrant epigenetic events as well as the prospect of treating cancer with epigenetic 
pharmaceuticals.   
 
1.2 Acute Myeloid Leukemia 
Normal mammalian hematopoiesis involves the differentiation of blood cells from a 
single pluripotent stem cell (Figure 1.1).  AML is a hematological malignancy associated with a 
defect in the maturation process whereby myeloid precursors are no longer converted into white 
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blood cells, but remain immature.  This malignancy usually occurs in the bone marrow.  The 
disease primarily occurs in adults, having equal frequency in males and females, with the 
incidence rising as age increases. (Alderson, 1980).  The incidence rates of AML are relatively 
stable over time, however there is a slight increase in incidence in the older population.  
Although AML survival rates in the young have almost doubled, there is still a low survival rate 
in both the younger and eldery population (Xie et al, 2003).  
The exact etiology of AML is unknown, however environmental factors and chemical 
exposure are associated with the disease. Benzene is one of the chemicals with the strongest link 
to AML, having its own subclassification of benzene-induced AML (Natelson, 2007).  Down’s 
syndrome is also a known risk factor for AML, as children with Down’s syndrome have a 20-
fold increased risk of developing leukemia.  The mechanism of this increased risk is unknown, 
however several hypotheses including chromosomal instability and gene expression 
dysregulation due to the trisonomy 21 have been proposed (Robison, 1992; Fong and Brodeur, 
1987).  Like other leukemias, the true etiology of AML most likely involves a combination of 
genetic and environmental factors. 
 
1.3 Chronic Myeloid Leukemia 
 Chronic Myeloid Leukemia is a myeloproliferative disorder which affects all lineages of 
hematopoiesis.  This disease is defined by the presence of the BCR-ABL oncogene.  This 
oncogene is formed when a translocation occurs between chromosomes 9 and 22, to form the 
Philadelphia chromosome (Sawyers, 1999).   
 The incidence of CML is 1-1.5 per 100,000 people and accounts for 15-20% of all adult 
leukemias.  CML can be diagnosed at any age, however most people are in their 50’s or 60’s at 
diagnosis.  The death rates of people affected with CML is relatively low, with only 490 deaths 
predicted in the coming year in the United States.  This is mostly due to the efficacy of kinase 
inhibitors, which specifically target the kinase activity of the BCR-ABL oncogene (Sessions, 
2007). 
 Patients are generally asymptomatic at presentation, and generally report to a physician 
for an unrelated matter.  Fatigue is a common symptom, however it is an elevated white blood 
cell count which leads to the eventual diagnosis of CML (Sessions, 2007). 
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Figure 1.1.  Mammalian Hematopoiesis.  Illustrated are the various differentiation pathways of 
the major types of blood cells.  Normal hematopoiesis involves the differentiation of all cells 
from a single pluripotent stem cell (Scott, 2005). 
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CML can be divided into two phases, a chronic phase and a blast phase. Untreated 
patients remain in the chronic phase for two to five years, and survive upon entering blast phase 
for three to six months.  The definition of each phase varies slightly, however chronic phase is 
defined as the patient having less than 15% blasts, less than 20% basophils and less than 30% of 
blasts and promyelocytes in both peripheral blood and bone marrow (Druker et al., 2006; 
O’Brien et al., 2003).  Once CML progresses to blast crisis, the symptoms closely resemble an 
acute leukemia.  The World Health Organization defines blast phase as being when blasts have 
exceeded 20% of all cells in the bone marrow and periphery, extramedullary blast proliferation 
and large clusters of blast cells in bone marrow biopsies (Jaffe et al., 2001). 
 Imatinib, a kinase inhibitor, is very effective for treatment of CML, however patients 
often develop resistance to the drug quickly, creating the need for new treatments to be 
developed (Lee et al., 2008). 
 
1.4 The Molecular Basis of Cancer 
There are six characteristics which define a cell as malignant: self-sufficiency in growth signals, 
insensitivity to growth-inhibitory signals, evasion of programmed cell death, limitless replicative 
potential, sustained angiogenesis and tissue invasion, and metastasis (Hanahan and Weinberg, 
2000).  Studies have revealed that these characteristics are obtained through the activation of 
oncogenes or the silencing of tumor suppressor genes. Proto-oncogenes are genes which 
normally have no detrimental effect, however, mutations and deregulation can cause proto-
oncogenes to become oncogenes. An oncogene is a protein encoding gene which causes the 
onset of cancer (Todd and Wong, 1999).  Tumor suppressor genes are genes which normally 
perform a repressive role in the cell.  Aberrant silencing of tumor suppressor genes causes 
uncontrolled growth and can lead to cancer.  The irregularities that occur in oncogenes and tumor 
suppressor genes provide a foundation for diagnosis and treatment (Weinberg, 1994). 
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1.4.1 Tumor Suppressor Genes 
 The protein products of tumor suppressor genes inhibit the proliferation of cells, and thus 
are very important to both normal cell growth and transformation of cells. When a cell loses its 
ability to produce a tumor suppressor, it no longer processes certain growth antagonizing signals 
from outside the cell and growth becomes uncontrolled (Massague, 1990). 
One of the most famous and most studied tumor suppressor gene is the Retinoblastoma 
gene.  If one copy of the gene is lost through deletion or translocation, a functional protein is still 
created from the remaining allele. If the second allele is also lost or silenced, then no functional 
protein can be made and cancer develops.  This concept forms the “two hit” hypothesis 
postulated by Alfred Knudsen in 1971 (Knudsen, 1971).  If the absence of the first allele is 
caused by a deletion, offspring have the potential to inherit this defect, putting them at an 
increased risk, as only one additional event is necessary to induce cancer.  It is also possible for a 
dominant negative mutation to occur.  In this case a mutation arises in the first allele which 
creates a non functional protein with the ability to interfere with the function of the remaining 
intact proteins function (Blagosklonny, 2000).   
 
1.4.2 Regulation of Apoptosis 
 Apoptosis is a cascade of events which leads to the programmed death of a cell.  When 
properly regulated, apoptosis protects the body from the effects of such occurrences as DNA 
damage, oxidative stress, and viral infections by sacrificing affected cells to prevent adjacent 
healthy cells from acquiring the defects of the damaged cells (Miller, 1997).  Apoptosis also 
plays an important role in embryological development, tissue homeostasis and immune cell 
education (Vaux and Korsmeyer, 1999).  The importance of apoptosis is suggested by the large 
amount of genes involved, approximately 200 genes, or 0.6% of the entire genome, though this is 
thought to be an underestimation (Reed et al., 2003). 
Cellular transformation can result from the activation of oncogenes or the disruption of 
tumor suppressor genes that regulate apoptosis.  Often tumorigenesis occurs because of an 
inhibition of apoptosis rather than an increase in proliferation rates.  Inhibition of apoptosis 
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creates excess cellular growth even though proliferation rates do not increase (Hanahan and 
Weinberg, 2000).   Deregulation of apoptosis is not only implicated in cancer but also in various 
other conditions, such as neurodegenerative disease (Yu and Zhang, 2004).  
 
1.4.3 Multistep Molecular Carcinogenesis 
Carcinogenesis does not occur from one event; it is the accumulation of many 
abnormalities occurring over time.  There are at least three steps which can be defined in the 
process of carcinogenesis: initiation, promotion, and progression.  It is estimated that most 
cancers require at least five or six genetic mutations for carcinogenesis to occur (Fearon and 
Vogelstein, 1990). 
A model was proposed in 1990 for cancer, which suggested that as a cell moves through 
the various stages of malignancy (hyperplasia, metaplasia, etc.), various genetic “hits” are 
acquired, which affect multiple genes in multiple pathways (Fearon and Vogelstein, 1990).  
Similarly, Knudsen’s previously mentioned “two hit” hypothesis postulates that there is more 
than one event necessary to perpetuate carcinogenesis (Knudsen, 1971).  For instance, in the first 
hit one allele is lost due to a deletion, and in the second hit the other allele becomes 
hypermethylated at the promoter region.  Multistep molecular carcinogenesis also refers to an 
accumulation of mutations, which together form the basis for tumor formation.  The model for 
multistep molecular carcinogenesis is illustrated in Figure 1.2.  As the neoplasm evolves into a 
malignant cancer, multiple mutations occur combined with a decrease in overall DNA 
methylation, an increase in promoter region DNA methylation, and a change in histone 
modifications (Esteller, 2008). These different mechanisms are discussed in subsequent sections. 
Understanding the order that genetic “hits” occur is essential to the understanding of tumor 
formation and progression. 
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Figure 1.2.  Multistep Molecular Carcinogenesis.  As cancer progresses there is a decrease in 
overall DNA methylation, an increase in promoter region CpG island DNA methylation, and an 
altered histone modification pattern.  5mC denotes 5-methyl cytosine.  
 
1.5  Epigenetics 
The term “epigenetics” was coined in the 1940’s by Conrad Waddington, and literally 
translates to “above the genome” (Slack, 2002).  It involves two concepts: 1) the study of 
heritable developmental processes in an organism and 2) the study of heritable changes in 
expression that occur without any change in the genomic DNA sequence.  Both concepts are 
concerned with the study of heritable changes that are not coded for within the DNA sequence. 
 
1.5.1 DNA Methylation 
DNA methylation occurs when the C5 position of a cytosine gains a methyl group 
(Figure 1.3).  DNA methylation occurs in the promoter region in areas called CpG islands.  CpG 
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islands are cytosine-guanine dinucleotide rich areas. CpG islands are usually not methylated in 
normal DNA, as active transcription appears to protect this area from methylation (Clark and 
Melki, 2002; Herman and Baylin, 2003; Weber et al., 2007).   CpG islands comprise 1-2% of the 
genome, existing in approximately 40-50% of the promoter regions of genes and were originally 
arbitrarily defined to be areas with 50% CG content and approximately five times the normal 
occurrence of the CG dinucleotide (Gardiner-Garden and Frommer, 1987).  In order to avoid 
including such CG-rich areas as Alu-repetitive elements and intragenomic parasites, the criteria 
has recently been modified to be more stringent.  More recent criteria for CpG islands include 
regions of DNA of greater than 500 bp with a G+C content equal to or greater than 55% and 
observed CpG/expected CpG ratio of 0.65  (Takai and Jones, 2002).  
In cancer, the genome undergoes an overall hypomethylation (Feinberg and Vogelstein, 
1983) however promoter regions of tumor suppressor genes are often hypermethylated (Greger et 
al., 1989; Sakai et al., 1991).  DNA methylation at the promoter region of genes is associated 
with gene repression.  DNA methylation is also responsible for genomic imprinting (Feinberg et 
al, 2002) and the formation of Barr bodies in females (Reik and Lewis, 2005).   
 
 
 
 
 
Figure 1.3.  Chemical Structures of Pyrimidine Nucleosides and 5-Methyl-Cytidine. Illustrated 
are the chemical structures and names of the common pyrimidine nucleosides, thymidine and 
cytidine, and 5-methyl-cytidine. The grey box highlights the methyl group attached to the 
carbon-5 of cytidine.  Note: Thymidine is depicted as deoxy in this figure   
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1.5.1.1 DNA Global Hypomethylation 
The first epigenetic phenomenon discovered in relation to cancer was the low level of 
methylation in tumor cells compared to their normal counterparts (Feinberg and Vogelstein, 
1983).  The overall decrease in DNA methylation is due to the demethylation of introns and 
exons, which allows alternate versions of mRNA to be transcribed (Feinberg and Tycko, 2004).  
As a neoplasm develops, the degree of hypomethylation increases as the neoplasm progresses 
from benign to invasive.  This increase in hypomethylation is coupled with an increase in 
promoter region DNA methylation (Figure 1.2).  
 
1.5.1.2 CpG Island Hypermethylation 
Site specific DNA methylation was first discovered in 1986 with studies done on the 
calcitonin gene (Baylin et al, 1986).  This study determined that 5’ promoter region methylation 
of certain residues is linked to a tumor state in lung cancer and lymphoma.  Aberrant 
hypermethylation of tumor suppressor genes was also observed in many other carcinomas such 
as renal (Herman et al., 1994), AML (Herman et al., 1996), breast (Ottaviano et al., 1994), 
ovarian (Esteller et al., 2000), prostate (Lee et al., 1994), and brain (Bachman et al., 1999).  
It is still not clear whether DNA methylation is a spontaneous event or whether events 
predispose an individual to aberrant hypermethylation.  One event that appears to predispose 
people to hypermethylation is age.  In young people, the promoter regions of certain tumor 
suppressor genes are slightly methylated, however, as a person ages, DNA methylation increases, 
with the highest amount of DNA methylation observed in cancer development (Toyota et al., 
1999).   
Currently DNA hypermethylation markers are being investigated as prognostic factors, 
diagnostic tools, and treatment response predictors (Esteller, 2008).  DNA hypermethylation also 
has a role in cancer treatment. Like genetic mutations, DNA hypermethylation allows the tumor 
to thrive in its environment better, however unlike genetic mutations, DNA hypermethylation is 
reversible.  This makes it a target for new theurapeutic drugs.  Currently DNA methylation 
inhibitors 5-aza-cytidine (Vidaza) and 5-aza-deoxycytidine (decitabine) have been approved for 
clinical use in leukemia and myelodysplasic syndrome (Mack, 2006; Muller et al, 2006; Oki et 
al, 2007).   
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1.5.1.3 Mammalian DNA Methyltransferases 
The major enzymes involved in DNA methylation are DNA methyltransferases (DNMT). 
When DNA methylation occurs, the cytosine is everted from the DNA helix and placed into the 
active site of the DNMT.  DNMTs use the methyl donor S-adenosyl-L-methionine to methylate 
the DNA (Bestor, 2000).  In mammals, three families of DNA cytosine-5 methytransferase 
enzymes have been discovered: DNMT1, DNMT2, and DNMT3a and DNMT3b.   
DNMT1 is the largest methyltransferase, with a molecular mass of 184 kDa (Smith et al., 
1992).  DNMT1 has a regulatory domain in the amino-terminal two thirds of the protein and the 
catalytic domain in the carboxy-terminal region (Yen et al., 1992).  The catalytic region is 
similar among all known methyltransferases (Kumar et al., 1994).  In proliferating cells, 
DNMT1 is involved in a process known as maintenance methylation.  This process ensures 
reciprocal methylation of the newly synthesized daughter strand during replication (Leonhardt et 
al., 1992).  Disruption of DNMT1 in mice results in abnormal imprinting (Li et al., 1993), 
embryonic lethality, greatly reduced levels of DNA methylation (Li et al., 1992), and activation 
of endogenous retroviruses (Walsh et al., 1998).  DNMT1 abnormalities are found in colon 
cancer (Rhee et al., 2000), lymphoma (Lee et al., 2001), and pancreatic cancer (Peng et 
al.,2005).  DNMT1 is able to bind to the histone methyltransferase SUV39H1, and HP1, which 
suggests a direct link between DNA and histone methylation (Fuks et al., 2003a).   
  In comparison to DNMT1, DNMT2 is much smaller, with a predicted molecular weight 
of 45 kDa.  DNMT2 lacks the large amino terminal domain but contains all of the conserved 
methyltransferase motifs.  Until recently the function of DNMT2 has been largely unknown, and 
it still remains controversial. DNMT2 knockout mice show no defects or reduction in global 
methylation levels (Okano et al., 1998).  A recent study showed that DNMT2 is involved in 
methylation of tRNA, and suggested that it is also important in embryo development in zebrafish 
(Rai et al.,2007). 
De novo DNA methylation was confirmed by the discovery of DNMT3a and DNMT3b.  
Both of these methyltransferases are crucial for embryonic development and for the methylation 
during embryogenesis, which establishes the somatic methylation pattern of the organism 
(Okano et al., 1999).  DNMT3a and 3b are intermediate in size (100-130 kDa) compared to 
DNMT1 and DNMT2 and possess a smaller amino terminal region.  DNMT3a associates with 
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histone 3 lysine 9 (H3K9) methylation activity (Fuks et al., 2003a).  This complex most likely 
contains the histone methlytransferase SUV39H1, as DNMT3a binds to SUV39H1 in vivo (Fuks 
et al., 2003a).  DNMT3b abnormalities are found in bladder cancer, breast cancer, colon cancer, 
lung cancer (Beaulieu et al., 2002), and hepatocellular carcinoma (Saito et al., 2002). 
 
1.5.1.4 Mammalian Methyl-CpG Binding Proteins 
DNA methylation is not believed to be the primary cause of carcinogenesis in tumor 
cells.  Instead it is believed that DNA methylation allows the chromatin to become “locked in” a 
state of transcriptional repression, which involves other mechanisms along with DNA 
methylation.  Many of the complexes required to initiate transcription are not present at the 
promoter when methylation is present, which results in a state of gene repression. There are 
factors which bind methylated DNA called methyl binding proteins that provide the basis for the 
DNA to transition into an inactive form (Bird, 2002).  
  A family of five methyl CpG binding proteins has been characterized, each of which has 
a methyl CpG binding domain similar to that of MeCP2 (Nan et al, 1993; Cross et al, 1997; Nan 
et al., 1997; Hendrich and Bird, 1998).  Four members of this family, MB1, MB2, MB3 and 
MeCP2 are implicated in methylation dependent repression of transcription.  MB3 shares a 70% 
amino acid sequence similarity to MB2 and contains a methyl binding domain (MBD) motif but 
is unable to specifically recognize methylated DNA (Hendrich and Bird, 1998).  There is a fifth 
MBD protein, Kaiso, which targets methylated DNA and brings about transcriptional repression, 
but it differs in that it binds DNA through a zinc finger motif (Prokhortchouk et al, 2001). 
Instead of being involved in transcriptional silencing, MB4 is involved in DNA repair.  MB4 has 
a preference for binding 5-methyl-CpG-to-TpG mismatches, which indicates a role in the 
minimization of mutations at 5-methyl-CpG (Hendrich et al, 1999).  Also, MB4 knockout mice 
have a significantly increased rate of CpG mutations and tumorigenesis (Millar et al, 2002). 
MeCP2 was the first MBD to be cloned and the second MBD to be discovered (Lewis et 
al, 1992).  It is also the protein from which the MBD motif is defined (Nan et al, 1993).  MeCP2 
is located at Xq28 and is highly abundant (Nan et al., 1997).  The colocalization of MeCP2 to the 
nucleus with methylated DNA indicates the involvement of MeCP2 in DNA methylation 
mediated repression.  MeCP2 associates with and facilitates H3K9 methylation by bringing 
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histone methyltransferase activity to the hypermethylated promoter of a DNA methylated gene 
that it regulates (Fuks et al., 2003b).   
MBD1 is unique among MBD proteins as it represses transcription in both methylated 
and unmethylated promoter regions (Fujita et al., 1999).  MBD1 is similar to MeCP2 in that it is 
an abundant chromosomal protein (Ng et al., 2000), which contains a transcriptional repression 
domain (Fujita et al, 1999; Ng et al., 2000).  However, a proportion of its repression activity 
relies on recruitment of HDAC activity (Patra et al, 2003).   
MBD2 is part of the methyl-CpG binding protein 1 complex (Ng et al., 1999), which 
represses transcription in a methylation density dependent fashion (Bird and Wolffe, 1999).  
MBD3 does not have methyl-CpG binding capacity, however, it exists in an abundant 
nucleosome remodelling and histone deacetylation corepressor complex in humans (Zhang et al., 
1999).  This complex can be recruited to DNA by several different repressor proteins and is 
essential to embryogenesis (Ahringer, 2000). 
MBD proteins are present at the hypermethylated promoter regions of genes in 
hepatocellular carcinoma (Bakker et al., 2002), colon cancer (Magdinier and Wolffe, 2001), 
bladder cancer (Nguyen et al., 2002) and T-cell leukemia cell lines (El-Osta et al., 2002).  Upon 
treatment with Decitabine, a DNA methylation inhibitor, promoter demethylation occurs at the 
p16 locus, which is accompanied by the release of MBD proteins (Magdinier and Wolffe, 2001; 
Nguyen et al., 2002).  This is also associated with a local enrichment of acetylation of histones 
H3 and H4, suggesting that the recruitment of MBD proteins to the hypermethylated promoter 
regions of tumour suppressor genes also involves the deacetylation (or the inhibition of 
acetylation) of histones.  This role is also supported by the binding of MBD1 to a histone 
methyltransferase SUV39H1 and HP1, a methyl lysine binding protein.  This complex is 
believed to contain HDAC1 or HDAC2 as well.  MBD1 tethers the MBD1-SUV39h1-HP1 
complex to methylated DNA, which causes MBD1 dependent transcriptional repression (Fujita 
et al., 2003).  This finding is important as it creates a direct link between DNA methylation, 
histone methylation, and histone acetylation. 
 
1.5.1.5 Decitabine 
Inhibitors of DNA methylation rapidly reactivate expression of genes silenced by DNA 
hypermethylation. 5-azacytidine and its analog 5-azadeoxycytidine (decitabine) were the first 
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DNA methylation inhibitors to be characterized (Sorm et al., 1964) (Figure 1.4).  They were 
initially developed as chemotoxic reagents, however it was soon discovered that they have the 
ability to inhibit DNA methylation and to induce gene expression and differentiation in cells 
(Constantinides et al., 1977; Jones and Taylor, 1980).  In AML and MDS, the p15 promoter 
region is hypermethylated; treatment with Decitabine results in demethylation of the promoter 
region and re-expression of the gene (Daskalakis et al., 2002).  
Upon entering the cell, both analogs are changed into the deoxynucleotide form and are 
incorporated into newly synthesized DNA upon replication.  They are therefore most active in 
the S phase of cells.  DNMTs become covalently linked to the modified bases and are unable to 
methylate DNA any further (Jones and Taylor, 1980; Zhou et al., 2002).  This covalent 
attachment is responsible for the toxicity of decitabine (Michalowsky and Jones, 1987). 
Decitabine has been approved for clinical use in myelodysplastic syndrome and leukemia (Mack, 
2006; Muller et al., 2006; Oki et al., 2007), however decitabine is highly toxic to patients 
(Stresemann and Lyko, 2008). 
 
1.5.2 Post Translational Histone Modification 
Eukaryotic chromosomes exist as a DNA:protein complex.  There are two types of 
chromatin: heterochromatin, a highly condensed compact form of chromatin linked to 
transcriptional repression, and euchromatin, a more open form of chromatin linked to 
transcriptional activation (Wolffe and Kurumizaka, 1998). 
 
1.5.2.1 Nucleosomes and Chromatin Organization 
 
The histone is the most massive component of chromatin.  This protein component of the 
DNA:protein complex consists of 5 families: H1, H2A, H2B, H3 and H4. The DNA is wrapped 
around a nucleosome core, which is then packed into an octet, consisting of two copies each of 
H2A, H2B, H3 and H4 (Kornberg, 1974).  The DNA forms two complete left hand turns around 
the histone by binding to the positively charged residues on the amino tails of the histones. 
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Figure 1.4.  Chemical Structures of Common DNMT Inhibitors.  Illustrated are the common 
chemical structures and names of cytidine analog inhibitors of DNA methylation.  
 
 
 
The H1 histone is the linker histone and is responsible for binding the DNA in a cavity of 
the core particle where DNA both enters and exits the nucleosome (Allan et al., 1980). 
In order to successfully regulate transcription, several multisubunit and protein 
complexes act upon the chromatin.  Chromosomal segregation and repair require chromatin 
manipulation and it is evident that covalent modifications of regional histones play a part in this 
process.  The evidence for this stems from the reports correlating chromatin modifications to 
specific post-translational modifications of histone tails (Luo and Dean, 1999; Strahl et al., 
1999). 
Histone tails provide additional gene regulatory information that contributes to chromatin 
conformation (Strahl and Allis, 2000; Jenuwein and Allis, 2001).  The “histone code” hypothesis 
theorizes that specific modifications to histone tails act sequentially or in combination to form a 
code that is read by other proteins to bring about downstream events such as changes to 
transcription levels.  This thesis deals with two of these modifications, histone acetylation and 
histone methylation. 
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1.5.2.2 Histone Acetylation 
Acetylation of the lysines on histone tails was first discovered in the 1960’s (Allfrey et 
al., 1964).  This led to the discovery of the link between the acetylation state of the histone and 
transcriptional activation.  Histone acetylation is linked to transcriptional activation while histone 
deacetylation is linked to transcriptional silencing.  Acetylation of the lysines within the histone 
tail neutralizes the tails’ positive charge, allowing the chromatin to relax and providing space for 
the transcriptional machinery to access the DNA.  The acetylation state of the histone tail is 
reversibly regulated by two classes of enzymes: histone acetyltransferases (HATs) and histone 
deacetylases (HDACs)  (Archer and Hodin, 1999).  
The first acetyltransferase to be discovered was HAT1 (Kleff et al., 1995).  Although this 
enzyme was first found to localize to the cytoplasm, recent studies have found that HAT1 can 
also exist in the nucleus and participate in transcriptional regulation (Kelly et al., 2000).  There 
are three main families of histone acetyltransferases, which can be grouped according to their 
sequence similarity.  These families are Gcn5/PCAF, p300/CPB and MYST (Gray and Ekstrom, 
2001; Khochbin et al., 2001; Grozinger and Schreiber, 2002).  All three of these families can 
acetylate both histone tails and other proteins (Roth et al., 2001; Nakatani, 2001; Carrozza et al., 
2003). 
Histone deacetylases catalyze the removal of acetyl groups from the lysine on the tails of 
histones, which leads to chromatin condensation and transcriptional repression.  The first 
mammalian histone deacetylase was identified in 1996 by Taunton and colleagues (Taunton et 
al., 1996).  HDACs are divided into three classes based on their homology to HDACs in 
Saccharomyces cerevisiae in terms of size, cellular expression, and enzymatic domains.  Class I 
HDACs are expressed ubiquitously in various human tissues, are homologous to yeast Rpd3p, 
and can be found in the nucleus of cells.  Class II HDACs share homology with the yeast Hda1p 
and are shuttled between the nucleus and the cytoplasm.  Class III HDACs are homologous to 
Sir2 and are structurally unrelated to the other two classes of HDAC.  Class III HDACs have a 
unique enzymatic mechanism that requires NAD+ for activity (Mottet and Castronovo, 2008). 
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There are a lot of data supporting the link between aberrant histone acetylation and 
carcinogenesis.  Histone hypoacetylation has been directly linked to the initiation and/or 
progression of various cancers such as acute promyelocytic leukemia (Lin et al., 1998).   
 
1.5.2.3 Trichostatin A 
 Trichostatin A (TSA) is a histone deacetylase inhibitor (HDACI) (Figure 1.5).  It inhibits 
histone deacetylation at nanomolar levels, and also induces arrest in the G1 phase of the cell 
cycle (Yoshida et al., 1995).  Transcriptomic analysis reveals that only 2-17% of expressed 
genes are affected by HDACIs, which suggests that HDACIs affect only a specific subset of 
genes (Glaser et al., 2003; Della et al., 2001; Van Lint et al., 1996).  Genes involved in 
apoptosis, transcriptional regulation, cell cycle and growth, differentiation, cell migration, and 
angiogenesis are within this subset.  The cell cycle kinase inhibitor p21 is the most studied gene 
affected by HDACI.  In cells with silenced p21, HDACIs can induce p21 expression, arrest cells 
in G1 and increase promoter histone acetylation.  Although growth arrest is seen in almost all 
non-malignant cells, the response to HDACI in malignant cells is apoptosis (Mottet and 
Castronovo, 2008).  The exact mechanism by which HDACIs invoke this response is unknown, 
however HDACIs up regulate pro-apoptotic genes such as Bax, Bad, (Gillespie et al., 2006), and 
APAF-1 (Maiso et al, 2006).  
 
 
 
 
Figure 1.5.  Chemical Structure of Trichostatin A.  
 
1.5.2.4 Histone Methylation 
 Histone methylation is a common epigenetic modification found in all eukaryotes.  
Lysine residues on histone tails can be mono-, di-, or trimethylated.  Histone methylation is 
catalyzed by histone methyltransferases (HMTs), which introduce methyl groups onto lysine or 
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arginine groups present on the histone tail.  Mutational studies have shown that each HMT is 
functionally distinct (Tachibana et al., 2005).  The first HMT discovered was SUV39h1, which is 
responsible for trimethylation of lysine 9 of histone 3 (H3K9) (Rea et al, 2000).  Methylation of 
H3K9 is associated with transcriptional repression, while methylation of H3K4 is linked to 
transcriptional activation (Jones and Baylin, 2007).   
SUV39h1 uses monomethylated H3K9 as a substrate for trimethylation of the same 
residue (Peters et al., 2003).  The SU(VAR)3-9 Enhancer of zest Trithorax (SET) domain of 
SUV39h1 is responsible for the H3K9 methyltransferase activity.  There are two loci which code 
for SUV39h genes: SUV39h1 and SUV39h2. Although single SUV39h1 and SUV39h2 mice are 
viable, double null mice are born at only about 20-25% of the expected mendelian ratio, are 
growth retarded, have a predisposition to tumors, and show very unstable genomes due to a lack 
of histone methylation (Peters et al., 2001).  The ability of one locus to compensate for the loss 
of the other suggests the two loci have redundant functions (Rea et al., 2000).   
  SUV39h1 normally regulates the trimethylation of histones in pericentric chromatin, 
however SUV39h1 localization is not limited to this area of chromatin.  The retinoblastoma 
protein is able to recruit SUV39h1 and HP1 to the promoter regions of genes and cause 
transcriptional repression, which could include aberrant silencing of tumor suppressor genes 
(Nielsen et al., 2001). 
SUV39h1 is able to form a complex with HP1.  HP1 is a transcriptional repressor which 
recognizes and binds to areas of chromatin where SUV39h1-mediated methylation occurs.  HP1 
then recruits other transcriptional repression machinery such as HDACs and DNMTs (Wang et 
al, 2000).  It is reported that DNMT3a and DNMT3b co-localize with HDAC activity (Bachman 
et al., 2001), and that H3K9 methylation is required in order for DNA methylation to occur 
(Tamaru and Selker, 2001).  This suggests a model whereby H3K9 methylation by SUV39h1 
would be the first event in transcriptional silencing, followed by recruitment of HDACs and 
DNMT by HP1 to further silence the gene.  This complex may also contain a DNA methylation 
binding protein as MBD1 is able to form a complex with SUV39h1 (Fujita et al., 2003).   
Another important HMT is G9a. Unlike SUV39h1, which regulates trimethylation of 
histones in pericentric heterochromatin, G9a dominantly regulates mono- and dimethylation in 
euchromatic regions (Peters et al., 2003; Rice et al., 2003).  G9a is essential for genome-wide 
dimethylation levels of H3K9, which is crucial for the silencing of many genes (Tachibana et al., 
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2002).  Mutations in G9a are sufficient to reduce levels of mono- and dimethylated H3K9 in 
euchromatic regions. Localization of HP1 to pericentric heterochromatic regions is regulated by 
SUV39h1 methylation, however, there is also localization of HP1 proteins to euchromatic 
regions.  Upon mutation of G9a, there is a gross relocalization of HP1 proteins away from 
euchromatic regions, suggesting that G9a influences the recruitment of HP1 proteins to 
euchromatic regions (Tachibana et al., 2005).  G9a also stimulates DNMT1 activity (Esteve et 
al., 2006). 
 
 1.5.2.5 Chaetocin 
 Chaetocin is a specific inhibitor of SUV39h1 and the first specific inhibitor of an H3K9 
methyltransferase (Figure 1.6) (Greiner et al., 2005).  It was first isolated from the fermentation 
broth of Chaetomium minutum and belongs to a class of molecules called 3-6 epidithio-
diketopiperazines. Cells treated with chaetocin show a marked decrease in H3K9 dimethylation 
and trimethylation, due to decreased SUV39h1 activity.  Chaetocin provides for a unique tool to 
study the effects of inhibition of SUV39h1 to the transcriptional regulation of a cell.  
 Chaetocin has also shown promising anti-myeloma effects.  Chaetocin largely spared 
normal bone marrow, B-cells, and neoplastic B-chronic lymphocytic leukemia cells, while 
having a potent effect on myeloma cells.  This indicates a large degree of selectivity of the drug 
(Isham et al., 2007).   
 
1.5.2.6 Dominance of Epigenetic Events 
 Determining the order in which epigenetic events occur is vital to developing our 
understanding of transcription.  Currently it is known that treatment with decitabine is sufficient 
to induce expression of genes with heavily methylated promoter regions, while TSA alone is not 
able to induce expression.  This suggests that DNA methylation is dominant over histone 
acetylation (Kawamoto et al., 2008).  There have also been studies done suggesting that H3K9 
methylation must occur before DNA methylation, which would make H3K9 methylation the 
dominant transcriptional event (Tamaru and Selker, 2001).  TSA is able to potentiate the 
induction seen by decitabine, suggesting that histone acetylation is playing a role in gene 
silencing (Kawamoto et al., 2008).       
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Figure 1.6.  Chemical Structure of Chaetocin.  
1.6 RIZ1 
RIZ1 was first discovered in a functional screening for Retinoblastoma binding proteins 
(Buyse et al., 1995), then later as a GATA-3 binding protein (Shapiro et al., 1995) and as a DNA 
binding protein (Muraosa et al., 1996).  It belongs to a superfamily of proteins called nuclear 
protein methyltransferases (Xiao et al., 2003).   It contains eight zinc finger DNA binding motifs, 
a PR binding domain, an RB binding motif, a hormone receptor binding domain, an SH3 
domain, a GTPase domain, an acidic region, a proline-rich domain, and a PR domain (Figure 
1.7).  It contains 1710 amino acids, with a molecular mass of 280 kDa.   
The PR domain of RIZ1 is a ~100 amino acid region of the protein, present at the N-
terminus (Buyse et al, 1995).  This domain is homologous to the SET domain, a motif found in 
chromosomal proteins that modulate gene activities in yeast and mammals (Tschiersch et al., 
1994; Stassen et al., 1995).  PR domain-containing proteins have two products: one which 
contains the PR domain, and one which does not (Liu et al., 1997).  The RIZ1 gene has an 
alternate product, RIZ2, which is produced from an internal promoter (Figure 1.7).  The PR 
domain has H3K9 methyltransferase activity, which is linked to gene repression (Kim et al., 
2003).    
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RIZ1 can act as both a repressor and activator of gene expression.  When estradiol is 
absent, RIZ1 represses expression of estrogen sensitive genes and increases the amount of H3K9 
methylation present, however, in the presence of estradiol, RIZ1 is able to activate gene 
expression by binding to the estrogen receptor.  When this occurs, H3K9 methylation is 
decreased and H3K9 acetylation is increased at estrogen receptor targets, likely through the 
interaction of RIZ1 with HAT co-activators (Carling et al., 2004).  RIZ1 has the ability to induce 
G2/M cell cycle arrest and/or apoptosis.  Interestingly, this ability is not dependent on p53 or 
Retinoblastoma, which suggests RIZ1 is acting on an alternate pathway to induce apoptosis (He 
et al., 1997). There is a correlation between the differentiation of myeloid cell lines and an 
increase in RIZ1 expression (Gazzerro et al., 2001). 
 
 
Figure 1.7.  Domain Structure of RIZ1 and RIZ2.    AR is the acidic region, RB is the RB 
binding motif, HR is the hormone receptor binding domain, PRD is the proline rich domain.  
 
1.6.1 RIZ1 as a Tumor Suppressor 
The RIZ1 gene is located at the distal arm of chromosome 1 at 1p36, a region frequently 
deleted in numerous carcinomas (Buyse et al., 1996; Muraosa et al., 1996).  RIZ1 is silenced in a 
number of cancers (Table 1.1).  Epigenetic silencing is the most common method of RIZ1 
silencing, (Du et al., 2001; Carling et al., 2003; Chang et al., 2003; Oshimo et al., 2004) 
however deletion (Carling et al., 2003), frameshift mutations (Piao et al., 2000; Sakurada et al., 
2001; Tokumaru et al., 2003) and missense mutations (Steele-Perkins et al., 2001; Kim et al., 
2003) also occur.  This loss of expression is confined solely to RIZ1, as RIZ2 expression is 
unchanged (He et al., 1998; Jiang et al., 1999; Chadwick et al., 2000; Sasaki et al., 2002).  The 
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fact that RIZ1 but not RIZ2 is silenced in these carcinomas suggests that the silencing of RIZ1 is 
not a randomly occurring event, and that there may be selection of RIZ1 silencing over RIZ2 in 
tumor tissues (Huang, 1999).  Animal models where RIZ1 has been selectively knocked out 
show a wide variety of tumor development such as diffuse large B cell lymphoma (Steele-
Perkins et al., 2001).  
Loss of heterozygosity often occurs in the 1p36 region, where RIZ1 is located (Hofmann 
et al., 2001).  Loss of heterozygosity is the first “hit” of the two hit hypothesis; the second “hit” 
is the second allele being silenced by epigenetic means. 
 
Table 1.1.  Mechanisms of RIZ1 silencing 
Carcinoma Mechanism of Silencing Reference 
Acute Myeloid Leukemia DNA Methylation Sasaki et al., 2002 
Breast DNA Methylation Du et al., 2001 
Colon DNA Methylation Du et al., 2001 
Colorectum Frameshift Mutation Sakurada et al., 2001 
DLBL Missense Mutation Steele-Perkins et al., 2001 
Endometrium Frameshift Mutation Piao et al., 2000 
Hepatoma DNA Methylation Du et al., 2001 
Liver DNA Methylation Du et al., 2001 
Lung DNA Methylation Du et al., 2001 
Nasopharyngeal DNA Methylation Chang et al., 2003 
Neuroblastoma Missense Mutations Kim et al., 2003 
Osteosarcoma Missense Mutations Steele-Perkins et al., 2001 
Pancreas Frameshift Mutations Sakurada et al., 2001 
Parathyroid Tumors Deletion Carling et al., 2003 
Parathyroid Tumors DNA Methylation Carling et al., 2003 
Pheochromocytomas Deletion Carling et al., 2003 
Pheochromocytomas DNA Methylation Carling et al., 2003 
Stomach Frameshift Mutations Sakurada et al., 2001 
Stomach DNA Methylation Oshimo et al., 2004 
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2.  HYPOTHESIS AND SPECIFIC AIMS 
The aim of this study was to re-express a tumor suppressor gene, RIZ1, in human AML and 
CML cell lines.  In the process of doing so, it was a goal to elucidate a model by which 
transcriptional silencing can be reversed.  Three epigenetic drugs decitabine, TSA and chaetocin 
were used to investigate the dominance of three epigenetic events: DNA methylation, histone 
acetylation and histone methylation respectively.  The specific aims of my study are to 1) re-
express RIZ1 in two model cell lines 2) determine any phenotypic effects the three epigenetic 
drugs have on the cells 3) determine any epigenetic effects the drugs have on the cell and 4) 
determine any synergistic or antagonistic effects the drugs have on the cells.  There is evidence 
that histone methylation is the dominant event in transcriptional silencing, as it has been found 
that histone methylation is necessary for DNA methylation to occur (Tamaru and Selker, 2001).  
It was my hypothesis that histone 3 methylation at lysine 9 is the dominant event in 
transcriptional silencing, and that treatment with decitabine, TSA and chaetocin will induce RIZ1 
expression. 
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3.  MATERIALS AND METHODS 
3.1 Reagents and Suppliers 
The reagents used for experiments in this thesis were all molecular biology or reagent grade 
and are listed in Table 3.1. Several of the procedures used in this study were performed using 
commercially available kits, which are listed in Table 3.2.  Table 3.3 lists the companies from 
which all reagents and kits were obtained. 
 
3.2 Oligonucleotides 
Table 3.4 lists all primers used in this study, along with their optimal annealing temperature.  
All primers were purchased from IDT DNA. 
 
3.3 Cell Lines and Tissue Culture 
3.3.1 Cell Lines and Standard Culture Conditions 
The human AML cell line AML-193 and human CML-BP cell line K562 were purchased 
from the German Collection of Organisms and Cell Cultures (DSMZ).  AML-193 cells were 
cultured in Iscove’s modified Dulbecco’s medium (IMDM) with 20% (v/v) fetal bovine serum 
(FBS, Invitrogen) supplemented with 2 ng/mL granulocyte macrophage colony stimulating 
factor (GM-CSF) and 3 units/mL Interleukin-3 (IL-3) (R&D Systems).  K562 cells were cultured 
in IMDM medium with 10% (v/v) FBS.  All cultures contained 1% (v/v) penicillin/streptomycin 
solution (Gibco) and were maintained at 37°C and 5% CO2.  All cell culture media was supplied 
from Invitrogen.  Cells were incubated with decitabine, TSA or chaetocin for 72 hours.  An 
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equivalent volume of 50% (v/v) acetic acid, ethanol or DMSO was used as vehicle controls 
respectively. 
Table 3.1.  Reagents and Suppliers Used in This Study 
Reagent Supplier Name 
100 bp DNA ladder Fermentas 
5-aza-2’deoxycytidine Sigma-Aldrich 
acetic acid EMD Chemicals 
agarose Invitrogen Life Technologies 
boric acid EMD Chemicals 
Chaetocin Sigma-Aldrich 
dATP Fermentas 
dCTP Fermentas 
dGTP Fermentas 
DMSO Sigma-Aldrich 
dTTP Fermentas 
ethanol EMD Chemicals 
ethidium bromide Invitrogen Life Technologies 
fetal bovine serum Invitrogen Life Technologies 
GM-CSF R&D Systems 
HCl EMD Chemicals 
HotStarTaq Polymerase Qiagen 
IL-3 R&D Systems 
IMDM Invitrogen Life Technologies 
isopropanol EMD Chemicals 
loading dye 6X solution Fermentas 
methanol BDH 
MgCl2 Qiagen 
MTT reagent Invitrogen Life Technologies 
NaOH BDH 
nuclease free water Ambion 
PCR buffer 10X Qiagen 
penicillin/streptomycin 100X mix Invitrogen Life Technologies 
propidium iodide Sigma-Aldrich 
RNAse Worthington 
RNasin Promega 
SDS EMD Chemicals 
sodium bicarbonate BDH 
sodium borate EMD Chemicals 
Trichostatin A Sigma-Aldrich 
Trypan Blue Invitrogen Life Technologies 
iQ SYBR Green Supermix Bio-Rad 
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Table 3.2.  Commercially Available Kits Used in This Study 
Commercially Used Kits Company 
DNeasy Blood and Tissue Kit Qiagen 
EZ DNA Methylation Kit Cedarlane 
iScript cDNA Synthesis Kit Bio-Rad 
RNeasy Mini Kit Qiagen 
Table 3.3.  Names and Addresses of Suppliers  
Supplier Address 
Ambion Austin, Texas, USA 
BDH Chicoutimi, Quebec, Canada 
Bio-Rad Mississauga, Ontario, Canada 
Biosoft Box 1013, Great Shelford, Cambridge, GB, 
CB22 5WQ 
EMD Chemicals San Diego, California, USA 
Fermentas Canada Inc., Burlington, Ontario, Canada 
Invitrogen Life Technologies Burlington, Ontario, Canada 
Molecular Devices Sunnyvale, California, USA 
Promega Nepean, Ontario, Canada 
Qiagen Mississauga, Ontario, Canada 
R&D Systems Minneapolis, Minnesota, USA 
Sigma-Aldrich Oakville, Ontario, Canada 
Tree Star Inc. Ashland, Oregon, USA 
Worthington Freehold, New Jersey, USA 
Table 3.4.  Sequences and Optimal Annealing Temperatures of Primers Used in This Study 
Name Sequence Temp 
RIZ1-RT-F 5-ATTGATGCCACTGATCCAGAGA-3 56.0°C 
RIZ1-RT-R 5-GCTCTGTTGATTTCCAGTGGGA-3 56.0°C 
RIZ1-MSP-U-F 5-TGGTGGTTATTGGGTGATGGT-3 60.0°C 
RIZ1-MSP-U-R 5-ACTATTTCACCAACCCCAAGA-3 60.0°C 
RIZ1-MSP-M-F 5-GTGGTGGTTATTGGGCGACGG-3 68.0°C 
RIZ1-MSP-M-R 5-GCTATTTCGCCGACCCCGACG-3 68.0°C 
RIZ1-PYRO-F 5-TTTGGGATAGTGGGGAGA-3 64.0°C 
RIZ1-PYRO-R 5-GATTGGAGTTAAGATG-3 64.0°C 
Β-actin-F 5-GCCCCGCGAGCACAGAGC-3 59.0°C 
Β-actin-R 5-GCGGTTGGCCTTGGGGTTCAG-3 59.0°C 
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3.4 General Molecular Techniques 
3.4.1 Isolation of Total RNA From Eukaryotic Cells 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) which typically yielded 1-3 mg 
of RNA per 5x106 starting cells.  RNA pellets were dissolved in nuclease free water (Ambion). 
The concentration and purity of samples were determined by standard A260/A280 
spectrophotometric reading as well as by agarose gel electrophoresis. Samples were stored at -
80°C until needed. 
 
3.4.2 Isolation of DNA from Eukaryotic Cells 
Genomic DNA was isolated using the DNeasy Blood and Tissue kit (Qiagen).  The procedure 
was followed according to manufacturer’s instructions and yielded approximately 20 µg of DNA 
per 5 x 106 starting cells.  The concentration and purity was determined by standard   A260/A280 
spectrophotometric reading and stored at -20°C until needed. 
 
3.5 Reverse Transcription PCR (RTPCR) 
Total RNA was used as a template for the synthesis of cDNA using the iScript cDNA 
Synthesis kit (Bio-Rad) according to manufacturer’s specifications. Briefly, 1 µg of total RNA 
was added to a mix containing 4 µL 5X iScript Reaction Mix, 1 µL iScript Reverse Transcriptase 
and 1 µg RNA in a final volume of 20 µL. Synthesis of cDNA was completed by incubation at 
25°C for 5 minutes followed by 30 minutes at 42°C and 5 minutes at 85°C.  Samples were used 
immediately or stored at -20°C. 
Polymerase chain reaction (PCR) was performed in a final volume of 50 µL containing 
1µL of cDNA, 1X PCR Buffer (containing 1.5 mM MgCl2) (Qiagen), 1.5 mM MgCl2, 0.4 mM 
dNTP, 0.2 µM of each primer and 1 unit of HotStar Taq (Qiagen).  The amplification consisted 
of an initial Taq activation step of 95°C for 15 minutes followed by 35 cycles (30 for β-actin, 45 
for pyrosequencing) of (95°C for 30 seconds, annealing temperature for 30 seconds, 72°C for 
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one minute) and a final incubation of 72°C for 6 minutes.  Following amplification, 10 µL of 
PCR products were visualized using standard agarose gel electrophoresis.  Primers and annealing 
temperatures are listed in Table 3.4.  
 
3.6 Standard Agarose Gel Electrophoresis 
Standard DNA fragment gel electrophoresis was typically performed in 2% (w/v) agarose 
gels in 1X sodium borate buffer containing 0.5 µg/mL ethidium bromide.  The gel was run at 150 
volts for the appropriate amount of time required to obtain optimal resolution. Gels were 
visualized under ultraviolet light and digitally captured using a gel documentation system (Bio-
Rad). 
 
3.7 Real Time PCR 
PCR was performed in a final volume of 20 µL containing 0.3 µL cDNA, 66 ng of each 
primer, and 12.5 µL of iQ SYBR Green Supermix (Bio-rad).  The amplification consisted of 5 
minutes at 95°C followed by 40 cycles (95°C for 30 seconds, annealing temperature for 30 
seconds, 72°C for one minute).  RIZ1 transcript expression levels were compared to the 
amplification of a housekeeping gene hypoxanthine-guanine phosphoribosyltransferase.  Data 
was analyzed by the ΔΔCt method (Livak and Schmittgen, 2001). 
 
3.8 DNA Methylation Analysis 
3.8.1 Sodium Bisulfite Modification 
Genomic DNA was treated with sodium bisulfite reagent for downstream methylation 
analysis essentially as described elsewhere (Herman et al., 1996; Tao et al., 2002). This 
procedure was performed using the EZ DNA Methylation kit (Cedarlane).  2 µg of genomic 
DNA was modified per sample according to the manufacturer’s instructions.  Samples were 
stored at   -20°C until needed. 
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3.8.2 Methylation Specific PCR (MSP) 
DNA methylation within promoter associated CpG islands was determined by MSP 
following sodium bisulfite treatment of genomic DNA. PCR was performed in a final volume of 
50 µl containing 100 - 200 ng of bisulfite-treated DNA, 1x Qiagen PCR Buffer, 2.5 mM MgCl2, 
0.4 mM of each dNTP, 0.2 µM of each primer set, and 1 unit of HotStar Taq (Qiagen). The 
amplification consisted of a Taq activation step at 95°C for 15 min followed by 35 amplification 
cycles (94°C for 1 min, annealing temperature for 1 min, and 72°C for 1 min) and a final 
incubation at 72°C for 10 min. The 5’ CpG islands were identified using the online ‘CpG Island 
Searcher’ tool (Takai and Jones, 2003) and appropriate primers were designed near the major 
transcriptional start site of target genes using the online ‘MethPrimer’ tool (Li and Dahiya, 
2002).  The primer sequences and optimal annealing temperatures are listed in Table 3.4.  
Modified AML-193 DNA served as the methylated MSP positive control while modified THP-1 
DNA served as the unmethylated MSP positive control.  Following amplification, 10 µL of PCR 
products were visualized using standard agarose gel electrophoresis. 
 
3.9 MTT Assay 
Cell proliferation/cytotoxicity was measured by the [3-(4,5-dimentylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] (MTT) assay. Cells were plated in triplicate at 2 x 104 cells per 
well in a 96 well plate, cultured as described in section 3.3, and treated with a vehicle control, 4 
µM Decitabine, and/or indicated concentrations of TSA and Chaetocin for 72 hours.  Following 
the treatment period, 1/10 culture volume of 5 mg/mL MTT labelling reagent (Sigma-Aldrich) 
was added to each well and incubated for 4 hours at 37°C.  The resulting crystals were 
solubilized by adding 100 µL of solublization solution (10% (v/v) SDS, 0.01M HCl) to each well 
and incubating overnight at 37°C.  Spectrophotometric absorbance readings were then taken (570 
nm with 650 nm background subtraction) using a Spectramax 340 PC plate reader (Molecular 
Devices). 
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3.10 Cell Cycle Analysis 
Cell cycle analysis was performed by propidium iodide (PI) staining of DNA content. 
Cells were cultured as described in section 3.3, and treated with a vehicle control, 4 µM 
decitabine, and/or indicated concentrations of TSA and Chaetocin.  Briefly, 1 x 106 cells were 
washed in ice cold 1X PBA [1X PBS, 0.1% (w/v) bovine serum albumin, 0.02% (w/v) sodium 
azide] fixed in ice cold ethanol and incubated overnight at 4°C. Cell pellets were reconstituted in 
Triton-PBA [0.1% (v/v) Triton X-100, 1X PBA] for 3 min, pelleted by centrifugation, and 
incubated in 500 units/mL RNase working solution (Worthington) at 37°C for 45 min. Samples 
were stained 15 minutes in 0.6 mL PI working solution (0.05 mg/mL in PBA; Sigma) at room 
temperature and filtered through 35 µm nylon mesh into glass tubes for flow cytometry analysis.  
Ten thousand cells were gated and sorted according to DNA content, then analyzed the using 
FloJo software (Tree Star, Inc.) 
 
3.11 Trypan Blue Staining 
Cell viability was determined by Trypan Blue Staining.  Briefly, cells were cultured as 
above and treated with a vehicle control, 4 µM Decitabine, and/or indicated concentrations of 
TSA and Chaetocin.  10 µLs of the sample were then diluted 2X in Trypan Blue staining reagent 
(Invitrogen), and then counted using a hemocytometer (Spencer).   
 
3.12 Calcusyn 
 Synergy calculations were performed via Calcusyn software (Biosoft).  MTT data were 
inputted into the software and values generated using the software. 
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4.  RESULTS  
4.1 Expression and Methylation Analysis of Leukemia Cell Lines in Study 
 RIZ1 is silenced in both CML and AML cell patient material (Figure 4.1, 4.2) (Geyer et 
al., unpublished). Reverse transcription PCR and methylation specific PCR were conducted to 
confirm these results.  Three model cell lines were investigated: K562 (CML blast crisis), THP-1 
(acute monocytic leukemia) and AML-193 (AML). RIZ1 expression was shown to be absent in 
both K562 and AML-193, whereas RIZ1 expression was observed in THP-1 (Figure 4.3a). Two 
assays, methylation-specific PCR (MSP) and pyrosequencing, were used to determine the 
methylation status of the RIZ1 promoter region. For both assays, DNA was extracted from the 
cells and subjected to bisulfite modification, which changes all unmethylated cytosines to uracil, 
and subsequently to thymidine after PCR amplification. Bisulfite-modified DNA is used as a 
template for PCR with two sets of primers, one for unmethylated DNA and one for methylated 
DNA.  The primers for unmethylated DNA have all of the cytosines substituted with thymidine 
while the primers for methylated DNA retain all cytosine bases. MSP analysis revealed that in 
K562 the promoter is hemi-methylated, in THP-1 the promoter is unmethylated, and in AML-
193 the promoter is predominantly methylated (Figure 4.3b). Based on these initial results, K562 
and AML-193 were chosen as model cell lines in this study as they both had silenced RIZ1.   
 
4.2. Toxicity of Three Epigenetic Drugs in Human AML and CML Cell Lines 
Prior to analyzing the affects of decitabine, TSA, and chaetocin on RIZ1 expression and 
promoter methylation, the toxicity of these drugs was measured using trypan blue staining and 
MTT assays to determine acceptable dose ranges for this study. Trypan blue dye exclusion assay 
measures cell viability based on the ability of non-viable cells to absorb blue dye once their cell 
membrane is breached. 
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Figure 4.1.  Methylation Analysis of AML Patient and Normal Bone Marrow Samples.  A) RT-
PCR shows that RIZ1 mRNA transcripts are decreased in samples 2, 3, 4, 5, 6, 25 and 40 (top 
panel).  All cases showed similar β-actin mRNA transcript levels (bottom panel).  B) 
Methylation specific PCR of the RIZ1 promoter region in AML patient samples shows 
methylated (M) DNA in samples 5, 25 and 40, all of which have markedly decreased RIZ1 
mRNA transcript levels in the RT-PCR.  In contrast, all normal bone marrow samples show 
unmethylated (U) DNA in the promoter region of RIZ1 (Geyer et al., unpublished).
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Figure 4.2.  RIZ1 Expression in Bone Marrow of CML Patients.  a)  Immunohistochemical 
analysis of RIZ1 expression in matched bone marrow biopsies from patients in chronic phase or 
accelerated/blast crisis.  Brown staining indicates presence of RIZ1 b) RIZ1 expression in normal 
bone marrow and normal bone marrow staining in the absence of RIZ1 primary antibody 
(negative control). (Geyer et al., unpublished). 
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Figure 4.3.  Analysis of RIZ1 Expression and Promoter Methylation.  a)  cDNA of cell lines was 
subject to RT-PCR analysis for RIZ1 expression. β –actin was used as a loading control.  b) MSP 
analysis of modified DNA of three cell lines. M is an amplicon generated from primers specific 
to methylated RIZ1.  U is an amplicon generated from primers specific to unmethylated RIZ1. 
 Viability is determined by counting the number of blue cells versus total cell number. An 
MTT assay is a colorimetric assay that determines the activity of enzymes that reduce MTT to 
formazan. Reduction of MTT to formazan is a colorimetric process, with the dye changing from 
a yellow colour to a purple colour, which allows the results to be measured using a 
spectrophotometer.  Enzymes that catalyze the reaction are present in the mitochondria and are 
only active when a cell is viable, allowing a correlation between spectrophotometric readings and 
viability (Carmichael et al., 1987).  The MTT assay is the more sensitive of the two assays, as it 
measures the activity of enzymes within the cells, whereas a loss of viability will not be detected 
in the trypan blue assay until the cell membrane has been breached.  The two model cell lines, 
K562 and AML-193, were treated for 72 hours with varying doses of decitabine, TSA, and 
chaetocin and then subjected to trypan blue exclusion and MTT assays.  
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Figure 4.4.  Viability of AML-193 and K562 Cell Lines Treated with Decitabine.  (top) AML-
193 and (bottom) K562 cells were treated with indicated concentrations of decitabine for 72 
hours and then analyzed by the MTT assay (a, c).  Absorbanes shown were normalized to the 0 
µM condition. Samples were taken at indicated times and then analyzed by trypan blue assay (b, 
d).  Error bars represent standard deviation from three independent experiments.  ** Indicates 
p<0.005, * indicates p<0.05 relative to the 0 µM condition.  
Treatment of cells with 1 µM decitabine induced a statistically significant loss of viability 
in AML-193 as measured in the MTT assay (Figure 4.4a), while treatment of K562 cells with 2 
µM decitabine was required to induce a statistically significant loss of viability in K562 (Figure 
4.4c). This trend was not seen in the trypan blue exclusion assay (Figure 4.4b, Figure 4.4d) 
which suggested that decitabine was toxic enough to reduce cell proliferation in the MTT assay, 
but not enough to cause the cell wall to rupture.  To confirm that the doses of decitabine used in 
the viability assays are high enough to induce cell cycle arrest, I used propidium iodide staining 
to analyze the affect of decitabine on the cell cycle (Figure 4.5).  Treatment of K562 and AML-
193 cells with 4 µM decitabine caused an arrest in the G2 phase of the cell cycle.  This is 
accompanied by an increase in the percentage of cells in S phase and subG1 population and a 
decrease in the percentage of cells in the G1 phase. 
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Figure 4.5.  Cell Cycle of AML-193 and K562 Cell Line Treated with Decitabine. (top) AML-
193 and (bottom) K562 cells were treated for 72 hours with either (b, d) 4 µM decitabine or a 
(a,c) vehicle control.  Cells were then stained with propidium iodide and cell cycle analysis 
performed.  Shown is the percentage of cells in each phase of the cell cycle.  Cell cycle analysis 
was performed using the Watson algorithm of the FloJo software.  
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TSA showed significantly higher toxicity than decitabine in AML-193 and K562 cells.  In 
AML-193, treatment with 31 nM TSA caused a statistically significant loss of viability.  The 
viability continued to decrease until treatment with 125 nM TSA, where viability was reduced to 
0% of the control (Figure 4.6a).  This trend was similar in the trypan blue assay, where treatment 
with 62.5 nM caused the viability to decrease to 30% of control (Figure 4.6b). Treatment with 
250 nM over 72 hours caused complete cell death.  TSA was less toxic in K562 cells. Treatment 
of K562 cells with 31 nM of TSA induced a statistically significant loss in viability.  Treatment 
with 1 µM TSA caused complete cell death (Figure 4.6c).   This trend is also seen in the trypan 
blue assay.  Treatment with 250 nM TSA decreased viability to 90% of control cells while 
treatment with 1 µM TSA caused viability to decrease to 18% of control cells (Figure 4.6d).   
Chaetocin was more toxic than either decitabine or TSA.  Treatment of AML-193 cells 
with 10 nM chaetocin induced a statistically significant loss of viability (Figure 4.7a).  Viability 
continued to decrease until a dose of 20 nM chaetocin, where complete cell death occured.  This 
trend was observed in the trypan blue analysis with a slight loss of viability occurring at 10 nM 
chaetocin and 0% viability at 50 nM chaetocin (Figure 4.7b).  K562 was less sensitive to 
chaetocin than AML-193. K562 cells required a dose of 40 nM chaetocin to induce a statistically 
significant decrease in viability (Figure 4.7c). The decrease in viability continued until treatment 
with 80 nM chaetocin when complete cell death occurred.  Similar results are obtained using the 
trypan blue assay, where treatment with 50 nM chaetocin decreased viability by 30%.  This 
decrease in viability continued until treatment with 100 nM chaetocin where a minimum viability 
of 55% was obtained (Figure 4.7d).   
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Figure 4.6.  Viability of AML-193 and K562 Cell Lines Treated with TSA. AML-193 (a,b) and 
K562 (c,d) cells were treated for 72 hours with indicated concentrations of TSA and analyzed by 
the MTT assay.  Indicated is the absorbance observed normalized to the control (a, c).  Samples 
were taken at indicated time points and analyzed by trypan blue analysis (b, d).  Error bars 
represent the standard deviation from three independent experiments.  ** Indicates p<0.005, * 
indicates p<0.05 relative to the 0 nM condition.   
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Figure 4.7.  Viability of AML-193 and K562 Cell Lines Treated with Chaetocin. AML-193 (a,b) 
and K562 (c,d) cells were treated for 72 hours with indicated concentrations of Chaetocin and 
then analyzed by MTT.  Shown is the percentage absorbance of the control (a, c).  Samples were 
taken at indicated time points and analyzed by trypan blue analysis (b, d).  Error bars represent 
the standard deviation from three independent experiments. ** Indicates p<0.005, * indicates 
p<0.05 relative to the 0 nM condition. 
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4.3. Determination of the Median Dose of TSA and Chaetocin in MTT assays 
In order to determine the median doses for TSA and Chaetocin, MTT assays were carried out, 
and the fraction affected was calculated from Eq.1. 
  
Fraction Affected  = (absorbance of control-absorbance of sample)                                 (Eq. 1) 
                                 (absorbance of control-absorbance of highest dose) 
 
This effect is then plotted versus the dose to create a dose effect curve.  The median dose is 
found by taking the log of this curve, and applying equation 2.  The median dose is the antilog of 
the x intercept of the median effect plot. 
 
Log (fa/fu) = m log (D) – m log (Dm)                                                   (Eq. 2) 
 
In equation 2, fa is the fraction affected, fu is fraction unaffected, D is the drug dose, Dm is the 
median dose of the drug, and m is the slope of the line when plotting Log(fa/fu) versus LogD.   
The median effect plots for TSA and chaetocin are shown in Figures 4.8 and 4.9, respectively.  A 
relevant median dose could not be determined for decitabine because with the doses used in this 
study viability is not reduced enough to model a dose response curve.  The median dose for TSA 
in AML-193 and K562 cells was 33 nM and 128 nM, respectively (Figure 4.8).  The median 
dose for chaetocin in AML-193 and K562 cells was 10.3 nM and 23.8 nM, respectively (Figure 
4.9).  
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Figure 4.8. Median Effect Plot of AML-193 and K562 cells Treated with TSA.  AML-193 (a) 
and K562 (b) cells were treated with TSA for 72 hours and a median dose curve was created. (fa) 
Indicates fraction affected, (fu) indicates fraction unaffected, and (D) indicates dose.  
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Figure 4.9.  Median Effect Plot of AML-193 and K562 Cells Treated with Chaetocin.  AML-193 
(a) and K562 (b) cells were treated with chaetocin for 72 hours and a median dose curve was 
created. (fa) Indicates fraction affected, (fu) indicates fraction unaffected, and (D) indicates dose. 
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4.4 Methylation Status of the RIZ1 Promoter Region 
 Previously it was determined that the RIZ1 promoter region is methylated in both AML 
and CML cell lines (Figure 4.3). The RIZ1 5’-promoter region as well as CpG island and primer 
positions are illustrated in Figure 4.10.   If there are differences in the bands between control and 
treatment samples, those samples are sent for pyrosequencing.  Pyrosequencing allows for a 
quantitative analysis of the methylation present in the promoter region.  The DNA to be 
pyrosequenced is incubated with DNA polymerase, luciferase, ATP sulfurylase and substrates 
such as luciferan and adenosine phosphosulfate.  Upon incorporation of a nucleotide, a 
pyrophosphate is released, and is converted to ATP by ATP sulfurylase.  This ATP acts as the 
fuel for the luciferase mediated conversion of luciferan to oxyluciferan, which can be measured 
as this reaction releases light.  In quantifying methylation, the modified DNA is sequenced, and 
the percentage of methylated DNA is determined by the chemically-induced C/T differences 
(White et al, 2006). 
 
 
 
 
Figure 4.10.  Schematic of RIZ1 genomic DNA and primer binding sites.  The 5’ end of RIZ1 
genomic DNA is shown on top and exon 1 and CpG island locations are shown.  PCR primer 
locations for MSP analysis are indicated by arrows. 
 
Treatment with decitabine caused a decrease in overall RIZ1 promoter methylation in both 
cell lines.  This was most pronounced in the AML-193 cell line where treatment of cells with 16 
µM decitabine caused a decrease in average promoter region CpG methylation from 94% to 74% 
(Figure 4.11a).  Interestingly, upon analyzing the pyrosequencing results, the 8th CpG in Figure 
4.12 was not affected by the decitabine treatment and remains 100% methylated even when 
treated with 16 µM decitabine (Figure 4.12g).  Other than this CpG, no other discernable pattern 
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was evident.  All CpGs showed a similar loss of methylation within a few percentage points 
across the various treatments. 
  Treatment with decitabine lowered the amount of methylation in the RIZ1 promoter 
region from 39% to 30% in K562 cells.  Treatment of cells with decitabine caused a reduction in 
the amount of RIZ1 promoter DNA methylation (Figure 4.11).  Pyrosequencing analysis 
revealed that the 8th CpG which was resistant to demethylation in AML-193 was susceptible to 
demethylation in K562 (Figure 4.13).  Overall, AML-193 cells displayed a more gradual decline 
in DNA promoter region methylation upon treatment with decitabine, while K562 cells showed a 
large drop off upon treatment with 0.5 µM decitabine, and then slight changes from then on. 
TSA had no effect on the methylation status of the promoter region in either AML-193 or 
K562 (Figure 4.14) as shown by MSP. Since there was no change in methylation observed by 
MSP, pyrosequencing was not performed.   Treatment of AML-193 cells with chaetocin had no 
effect on the methylation status of the RIZ1 promoter region as determined by MSP (Figure 
4.15a).  Treatment of K562 cells with 2.5 nM chaetocin caused a small decrease in methylation, 
however the methylation began to increase with increasing dosage until treatment with 80 nM 
chaetocin, where the methylation increased from 39% to 65% (Figure 4.15b).  Treatment with 80 
nM chaetocin caused the most dramatic effects.  
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Figure 4.11.  Mean Methylation Status of the RIZ1 Promoter Region DNA of AML-193 and 
K562 cells upon Treatment with Decitabine.  AML-193 (a) and K562 (b) cells were treated for 
72 hours with indicated concentrations of decitabine, DNA was extracted, modified by bisulfite 
and pyrosequenced.  Shown is a histogram of the mean methylation percentages over entire 
region examined. 
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Figure 4.12. Pyrosequencing Analysis of 17 CpGs in RIZ1 Promoter Region of AML-193 Cells 
Treated with Decitabine. 
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(cont.) 
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(Figure 4.12. cont) 
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Figure 4.12.  Pyrosequencing Analysis of 17 CpGs in RIZ1 Promoter Region of AML-193 Cells 
Treated with Decitabine.  Cells were treated for 72 hours with the indicated concentrations of 
decitabine, DNA was extracted, modified by bisulfite and analysed by pyrosequencing.  
Pyrosequencing output indicates methylation percentage at various CpGs  
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Figure 4.13. Pyrosequencing Analysis of 17 CpGs in RIZ1 Promoter Region of K562 Cells 
Treated with Decitabine. 
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(Figure 4.13 cont.) 
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Figure 4.13. Pyrosequencing Analysis of 17 CpGs in RIZ1 Promoter Region of K562 Cells 
Treated with Decitabine. Cells were treated for 72 hours with indicated concentrations of 
decitabine, DNA was extracted, modified by bisulfite and sent for pyrosequencing. 
Pyrosequencing output indicates methylation percentage at various CpGs 
 
Figure 4.14. Methylation status of the RIZ1 promoter region DNA of K562 and AML-193 cells 
upon treatment with TSA. M is an amplicon generated from a primer specific for methylated 
RIZ1.  U is an amplicon generated from a primer specific for unmethylated RIZ1. (–) is PCR 
water negative control.  
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Figure 4.15. Methylation Status of the RIZ1 Promoter Region DNA of AML-193 and Mean 
Methlation Status of K562 Cells upon Treatment with Chaetocin.  a) AML-193 DNA was  
subjected to methylation specific PCR.  M is the amplicon generated from a primer specific for 
methylated RIZ1. U is the amplicon generated from a primer specific for unmethylated RIZ1. 
Water was used as a negative control for the two PCRs.  (b) Pyrosequencing analysis of K562 
DNA samples.  Displayed is the mean methylation percentage over the entire promoter region.  
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Figure 4.16. Pyrosequencing Analysis of 17 CpGs in RIZ1 Promoter Region of K562 Cells 
Treated with Chaetocin. 
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Figure 4.16. Pyrosequencing Analysis of 17 CpGs in RIZ1 Promoter Region of K562 Cells 
Treated with Chaetocin. Cells were treated for 72 hours with the indicated concentrations of 
chaetocin, DNA was extracted, modified by bisulfite and sent for pyrosequencing. 
Pyrosequencing output indicates methylation percentage at various CpGs 
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4.5 Induction of RIZ1 Expression using Epigenetic Drugs 
RIZ1 is silenced in both AML-193 and K562 cell lines (Figure 4.3).  Real time PCR was 
used to determine if decitabine, TSA or chaetocin have an effect on RIZ1 expression in these two 
cell lines.  Treatment of cells with 0.5 µM decitabine induced a statistically significant amount of 
RIZ1 expression in AML-193 cells.  RIZ1 expression increased in a dose dependant manner until 
treatment with 8 µM decitabine, where a dramatic 36-fold increase in RIZ1 expression was 
observed (Figure 4.17a).  In K562 cells, treatment with 4 µM decitabine induced a statistically 
significant increase in RIZ1 expression, with a maximum increase of 9 fold after treatment with 
8 µM decitabine (Figure 4.17b).  
Treatment with TSA had no effect on the amount of RIZ1 expression in either cell line.  
Treatment with up to 750 nM TSA was unable to induce any RIZ1 expression (Figure 4.18).   
Treatment with 80 nM chaetocin induced a statistically significant increase of RIZ1 expression 
in AML-193, which increased upon treatment with 100 nM chaetocin to 5-fold higher than 
untreated cells (Figure 4.19a).  In K562, treatment with 100 nM chaetocin induced a statistically 
significant difference (Figure 4.19b).  
 
4.6 Potentiation of TSA and Chaetocin with Decitabine on Cell Proliferation and Viability 
Previously, we had shown that at the concentrations used in this study, no median dose 
for decitabine could be established, and thus no claims of synergy or antagonism can be made for 
decitabine (Chou, 2006).  However, whether decitabine potentiates the effect of TSA and/or 
chaetocin on cell proliferation and viability can be determined.  
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Figure 4.17.  Effect of Decitabine treatment of AML-193 and K562 cells on RIZ1 expression 
AML-193 (a) and K562 (b) cells were treated with the indicated concentrations of decitabine for 
72 hours, RNA was extracted and real time PCR was performed.  Error bars represent the 
standard deviation of three independent experiments. * Indicates p <0.05, ** indicates p <0.005 
relative to the 0 µM condition. 
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Figure 4.18. Effect of TSA Treatment of AML-193 and K562 cells on RIZ1 expression.  AML-
193 (a) and K562 (b) cells were treated for 72 hours with the indicated concentrations of TSA, 
RNA was extracted and RTPCR was performed (µM).  (+) is THP-1 cell line, which is used as a 
positive control for RIZ1 expression. β-actin was used as a loading control. 
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Figure 4.19. Effect of Chaetocin Treatment of AML-193 and K562 cells on RIZ1 expression. 
AML-193 (a) and K562 (b) Cells were treated for 72 hours with indicated concentrations of 
chaetocin, RNA was extracted and real time PCR performed. Error bars indicate the standard 
deviation from three separate experiments.  *indicates p<0.05 relative to the 0 nM condition. 
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 To investigate if decitabine potentiated the effect of TSA and/or chaetocin on cell 
proliferation and viability, MTT assays were performed.  A plus decitabine and minus decitabine 
condition in each case was used.  The data was plotted on a median effect plot with the median 
effect being the antilog of the X intercept.  The median doses from the MTT assay of the drugs 
with and without decitabine were compared.  In AML-193, the median doses dropped for both 
TSA and chaetocin, suggesting that decitabine potentiated the effects of both drugs.  The median 
dose for TSA dropped from 33 nM to 21 nM, (Figure 4.20) (Table 4.1) while the median dose 
for chaetocin dropped from 10 nM to 5 nM (Figure 4.21) (Table 4.1).  In K562 the median dose 
for TSA was much higher than previously determined and therefore this should be investigated 
further.  (Figure 4.22).  Although the median dose for chaetocin was higher than previously 
determined, a trend was still seen.  The median dose for chaetocin dropped from 35 nM to 29 
nM, which indicates that decitabine potentiated chaetocin (Figure 4.23) (Table 4.1).  Overall, 
decitabine potentiated chaetocin in both AML-193 and K562 cell line, and potentiated TSA in 
AML-193 cell line, with no potentiation of TSA observed in K562. 
Table 4.1.  Median Doses for AML-193 and K562 Cell Lines Treated with TSA and Chaetocin 
in the Presence and Absence of Decitabine.  Cells were treated with TSA or chaetocin, in 
increasing concentrations in the presence or absence of decitabine for 72 hours.  Cells were 
analyzed by MTT and median doses generated. 
Cell Line +/- 
Decitabine 
Drug Median Dose 
(nM) 
Upper 95% 
Confidence 
Interval 
(nM) 
Lower 95% 
Confidence 
Interval 
(nM) 
AML-193 - TSA 33 41.1 21.89 
AML-193 + TSA 21 39.3 10.79 
AML-193 - Chaetocin 10 16.6 8.37 
AML-193 + Chaetocin 5 9.4 2.48 
K562 - TSA 436 461.2 413.7 
K562 + TSA 436 867.5 219.6 
K562 - Chaetocin 35 116.7 16.57 
K562 + Chaetocin 29 39.2 21.19 
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Figure 4.20.  Median Effect Plot of AML-193 cell line upon Treatment with TSA in the Presence 
or Absence of Decitabine. AML-193 cells were treated in the absence (a) or presence (b) of 
decitabine and a median effect plot was generated.  (fa) Indicates fraction affected, (fu) indicates 
fraction unaffected, and (D) indicates dose. 
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Figure 4.21.  Median Effect Plot of AML-193 cell line upon Treatment with Chaetocin in the 
Presence or Absence of Decitabine. AML-193 cells were treated in the absence (a) or presence 
(b) of decitabine and a median effect plot was generated  (fa) Indicates fraction affected, (fu) 
indicates fraction unaffected, and (D) indicates dose. 
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Figure 4.22.  Median Effect Plot of K562 cell line upon Treatment with TSA in the Presence or 
Absence of Decitabine. K562 cells were treated in the absence (a) or presence (b) of decitabine 
and a median effect plot was generated. (fa) Indicates fraction affected, (fu) indicates fraction 
unaffected, and (D) indicates dose. 
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Figure 4.23.  Median Effect Plot of K562 cell line upon Treatment with Chaetocin in the 
Presence or Absence of Decitabine. K562 cells were treated in the absence (a) or presence (b) of 
decitabine and a median effect plot was generated.   (fa) Indicates fraction affected, (fu) indicates 
fraction unaffected, and (D) indicates dose. 
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4.7 Synergy/ Antagonism of TSA and Chaetocin 
Synergy or antagonism was determined using Calcusyn software (Chou, 2006). Synergy is 
defined as an effect that is more than additive of the effect of the individual drugs and 
antagonism is defined as an effect that is less than additive of the effect of the individual drugs. 
 The equations used in Calcusyn software follow the Mass Action Law, which deals with 
the kinetics of chemical reactions (Chou, 2006).  MTT assays were conducted which contained a 
range of doses of both TSA and Chaetocin as indicated in Figure 4.24. The fraction affected was 
calculated as shown in section 4.3, and the CI value was calculated using Equation 3.  
                      CI =   _______(D)1___________ +    _____(D)2__________                                    (Eq.3)                                                                                                                                                                                                                                                   
(D)m 1[fa/(1-fa)]1/m1            (D)m 2[fa/(1-fa)]1/m2 
 
 
In Equation 3, CI is the combination index, D1 is the dose of the first drug, D2 is the dose of the 
second drug, Dm1 is the median dose of the first drug alone, Dm2 is the median dose of the second 
drug alone, fa is fraction affected when both drugs are used, m1 is the slope of the median effect 
plotline of the first drug and m2 is the slope of the median effect plotline of the second drug. The 
CI value denotes the extent of the synergism or antagonism, with a value of 1 indicating an 
additive effect, a value < 1 indicating synergy and a value > 1 indicating antagonism. 
Also, the CI value was calculated at different effect levels, denoted as ED values.  For 
example, ED75 is the CI value at the 75% fraction affected level.  For infectious diseases or 
cancer therapies, synergism at high effect levels such as ED90 is much more therapeutically 
relevant, and thus these values are reported here (Chou, 2006). The CI value for chaetocin and 
TSA at ED90 for AML-193 was 0.816, indicating synergy between the two drugs.  The CI value 
for chaetocin and TSA at ED90 for K562 was 0.392 (Table 4.2). The CI value was also 
determined in the presence and absence of decitabine. In both cell lines the CI increased upon 
addition of decitabine.  This indicates that decitabine interfered with the synergy between TSA 
and chaetocin (Table 4.2). 
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Figure 4.24.  Experimental Setup of Combination MTT Assays.  Boxes indicate doses which 
were used when TSA and Chaetocin were used in combination.  Dm indicates median dose. 
Table 4.2.  CI Values for TSA and Chaetocin in AML-193 and K562 Cell Lines.  Cells were 
treated for 72 hours with increasing concentrations of TSA plus chaetocin in the presence and 
absence of decitabine.  Cells were then analyzed by MTT.  Shown are the CI values for ED90.  
CI values <1 indicate synergism, >1 indicate antagonism 
Cell Line +/- Decitabine CI Value 
AML-193 - 0.816 
AML-193 + 2.200 
K562 - 0.392 
K562 + 0.655 
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4.8 Methylation Status of the RIZ1 Promoter Region Upon Treatment with Epigenetic 
Drugs in Combination 
AML-193 and K562 cell lines were treated with the drugs in combination to determine 
what affects the drugs have on the methylation status of the RIZ1 promoter region.  AML-193 
cells were treated with 4 µM decitabine, and/or 33 nM TSA and/or 10.3 nM chaetocin, which are 
the median doses for TSA and chaetocin.   Median doses were chosen in order to ensure 
appropriate viability would be obtained. Treatment with decitabine decreased the amount of 
DNA methylation present, while treatment with TSA or chaetocin had no effect on the 
methylation status of the promoter region (Figure 4.25a).  This trend was seen in the 
pyrosquencing analysis as well, where treatment with decitabine decreased the amount of 
methylation by 15-20% across various CpGs, where very little difference was seen across the 
various CpGs upon treatment with TSA or chaetocin (Figure 4.26c, Figure 4.26d).  Treatment 
with decitabine and TSA together decreased the amount of methylation present similar to that of 
decitabine treatment alone, with 71.6% methylation from a control value of 94% (Figure 4.25a). 
Examining the individual CpGs, this appears to be a universal occurrence.  Interestingly 
in all treatments there is no change in the methylation levels of the 5th CpG except for the 
decitabine + TSA treatment (Figure 4.26e). Treatment with decitabine plus chaetocin caused 
methylation levels to return to nearly control levels (92.1%) (Figure 4.25a).  Again, this effect 
occured across all CpGs except the 5th and 8th (Figure 4.26f).  Treatment with chaetocin and TSA 
together caused a slight drop in methylation to 90.9% (Figure 4.25a). 
Also, there was very little difference between treating cells with chaetocin plus TSA and 
treating cells with decitabine plus chaetocin either in overall methylation levels (Figure 4.25a) or 
pattern of methylation among the CpGs (Figure 4.26f, Figure 4.26g).    Treating cells with all 
three drugs together caused methylation to drop slightly from control levels to 88.9% 
methylation (Figure 4.25a).   
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Figure 4.25. Mean Methylation Status of RIZ1 Promoter Region DNA of AML-193 and K562 
cells upon Treatment with Decitabine, TSA and Chaetocin in combination.  AML-193 (a) and 
K562 (b) cells were treated with decitabine and/ TSA and/or for 72 hours.  DNA was extracted 
and pyrosequenced. Shown is the mean percentage methylation over the entire promoter region. 
D indicates decitabine, T indicates TSA and C indicates chaetocin.  
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Figure 4.26. Pyrosequencing Analysis of 17 CpGs in RIZ1 Promoter Region of AML-193 Cells 
Treated with Decitabine and/or TSA and/or Chaetocin 
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Figure 4.26 cont 
 
d)  
Chaetocin 
98% 98% 98% 97% 100% 96% 95% 100% 100% 93% 95% 96% 96% 91% 80% 97%
ES G T CG T
5
C AG T C
10
G T CGT
15
C TG T C
20
AG T CG
25
T CGG T
30
C AG T C
35
G A C T A
40
G T CG T
45
CG T C A
50
G T C TG
55
T CG T T
60
CG T
0
200
400
600
800
-200
A10 : YGGYGGYGYGGTYGYGGGYGTYGGGGTYGGYGAAATAGYGGYGGYGGYGGYGGTTTTYGGTG
 
e)  
Decitabine+TSA 
75% 73% 71% 71% 83% 71% 70% 100% 79% 72% 71% 70% 72% 66% 54% 72%
E S G T CGT
5
C AG T C
10
G T CG T
15
CTG T C
20
AGT CG
25
T CGG T
30
C AG TC
35
G A C T A
40
G T CG T
45
CG T C A
50
G TC TG
55
T CGT T
60
CG T
0
200
400
600
800
1000
1200
A11 : YGGYGGYGYGGTYGYGGGYGTYGGGGTYGGYGAAATAGYGGYGGYGGYGGYGGTTTTYGGTG
 
f)  
Decitabine+Chaetocin
95% 95% 93% 93% 100% 94% 93% 100% 100% 91% 92% 93% 93% 87% 75% 94%
E S G T CG T
5
C AG T C
10
G T CG T
15
C TG T C
20
AG T CG
25
T CGG T
30
C AG T C
35
G A C TA
40
G T CG T
45
CG T C A
50
G T C TG
55
T CG T T
60
CG T
0
200
400
600
800
A12 : YGGYGGYGYGGTYGYGGGYGTYGGGGTYGGYGAAATAGYGGYGGYGGYGGYGGTTTTYGGTG
 
  
 
 
 
 
(cont) 
 
 69 
 
 
 
g) 
TSA+Chaetocin
94% 94% 94% 93% 100% 94% 89% 100% 98% 90% 91% 92% 94% 86% 74% 92%
E S G T CG T
5
C AG T C
10
G T CG T
15
C TG T C
20
AG T CG
25
T CGG T
30
C AG T C
35
G A C T A
40
G T CG T
45
CG T C A
50
G T C TG
55
T CG T T
60
CG T
0
100
200
300
400
500
600
B1 : YGGYGGYGYGGTYGYGGGYGTYGGGGTYGGYGAAATAGYGGYGGYGGYGGYGGTTTTYGGTG
 
h)  
Decitabine+TSA+Chaetocin 
92% 92% 90% 89% 100% 90% 87% 100% 96% 88% 89% 89% 90% 84% 71% 89%
E SG T CG T
5
CAG T C
10
G TCG T
15
C TGT C
20
AG T CG
25
T CGG T
30
C AG T C
35
G A C T A
40
GT CG T
45
CGT C A
50
G T CTG
55
T CGT T
60
CG T
0
200
400
600
800
1000
1200
-200
B2 : YGGYGGYGYGGTYGYGGGYGTYGGGGTYGGYGAAATAGYGGYGGYGGYGGYGGTTTTYGGTG
 
 
Figure 4.26. Pyrosequencing Analysis of 17 CpGs in RIZ1 Promoter Region of AML-193 Cells 
Treated with Decitabine and/or TSA and/or Chaetocin.  DNA was extracted, modified by 
bisulfite and sent for pyrosequencing. Pyrosequencing output indicates methylation percentage at 
various CpGs. 
 
As seen previously, there were two CpGs which did not respond to the demethylation effects 
at all (Figure 4.26, 5th and 8th CpG).  The increase in methylation seen from treatment with 
decitabine to treatment with decitabine plus chaetocin suggested that chaetocin is able to increase 
the amount of DNA methylation present, and that this effect was simply masked by the already 
high percentage of methylation present in AML-193.Decitabine is not able to overcome the 
effects of chaetocin in the presence of TSA as the methylation level when there is treatment with 
all three drugs is similar to that of TSA plus chaetocin (Figure 4.25a). Except for the 5th and 8th 
CpG these effects were fairly homogenous across the CpGs examined. 
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   K562 cells were treated with 4 µM decitabine, and/or 128 nM TSA and/or 23.8 nM 
chaetocin.  Treatment with decitabine decreased RIZ1 promoter DNA methylation, TSA had no 
effect on methylation and chaetocin slightly increased the DNA methylation as previously seen 
with AML-193 cells (Figure 4.25b).  Treating cells with decitabine plus TSA decreased the DNA 
methylation levels to 25.8%, lower than decitabine treatment alone (Figure 4.25b).  Treating 
cells with decitabine plus chaetocin caused an increase of methylation over that of decitabine 
treatment alone to 34.2% (Figure 4.25b).  Treating cells with TSA plus chaetocin showed similar 
effects with 34.4% methylation while treating cells with all three drugs caused an increase in 
methylation to 44.6% (Figure 4.25b). Pyrosequencing analysis reveals that although the majority 
of the CpGs react with a degree of uniformity, CpG 8 often has a much more dramatic effect on 
it than the others.   
 
4.9 Treatment with Small Molecule Inhibitors in Combination Induces RIZ1 Expression  
RIZ1 was silenced in both AML-193 and K562 cell lines (Figure 4.3a).  In order to 
induce RIZ1 expression, cells were treated with the three small molecule inhibitors in 
combinations.  Doses were chosen to ensure appropriate viability of the cells for the assay.  
AML-193 cells were treated for 72 hours with combinations of 0.5 µM decitabine, 100 nM TSA, 
and/or 10 nM chaetocin.. Treating cells with decitabine plus TSA in AML-193 showed an 
increased amount of induction over both decitabine or TSA alone (Figure 4.28a). Treating cells 
with decitabine alone increased RIZ1 expression by 2 fold where treatment with decitabine plus 
TSA increased RIZ1 expression by 9 fold. Induction upon treating cells with decitabine plus 
chaetocin was also higher than when either drug is treated alone (Figure 4.28a), with induction 
increasing from 1.6 fold when decitabine is administered alone to 8.8 fold when decitabine and 
chaetocin were treated together. Treating cells with TSA plus chaetocin increased RIZ1 
expression slightly, with a 2.5 fold induction (Figure 4.28).  Treatment with all three drugs 
increased the amount of RIZ1 induction more than the drugs alone, but not as much as the when 
used in pairs (Figure 4.28a).   
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Figure 4.27. Pyrosequencing Analysis of 17 CpGs in RIZ1 Promoter Region of K562 Cells 
Treated with Decitabine and/or TSA and/or Chaetocin.     
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(cont) 
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(Figure 4.27 cont.) 
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g) 
TSA+Chaetocin
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Figure 4.27. Pyrosequencing Analysis of 17 CpGs in RIZ1 Promoter Region of K562 Cells 
Treated with Decitabine and/or TSA and/or Chaetocin. Cells were treated for 72 hours with 
decitabine, and/or TSA, and/or chaetocin.  DNA was extracted, modified by bisulfite and sent for 
pyrosequencing. Pyrosequencing output indicates methylation percentage at various CpGs.   
 
The largest amount of induction is seen when decitabine and TSA are treated together.  This 
correlated with the synergy data obtained from the MTT assays, where the CI values increased 
when all three drugs were present.  This suggested that the drugs did not function best when all 
three were present (Table 4.2).  
Many of the same trends were seen in K562. K562 cells were treated for 72 hours with 
combinations of 1 µM decitabine, 500 nM TSA and/or 50 nM chaetocin.  Treatment with 
decitabine plus TSA showed a larger induction that of each drug alone.  Decitabine plus TSA 
induced a 4 fold induction while decitabine alone only induces a 2 fold induction (Figure 4.28b).  
Treating cells with decitabine plus chaetocin also showed a larger induction than that of each 
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drug alone, having induced a 5 fold induction of RIZ1 expression (Figure 4.28b).  Treating cells 
with TSA plus chaetocin also showed increased induction over each drug alone, inducing a 2 
fold increase of RIZ1 expression (Figure 4.28b).  Treating cells with all three drugs together 
induces RIZ1 expression more than each drug alone, however not as well as any of the drugs in 
pairs (Figure 4.28b).    
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Figure 4.28. Effect of Decitabine, TSA and/or Chaetocin Treatment of AML-193 and K562 cells 
on RIZ1 expression. (a) AML-193 cells were treated for 72 hours with 0.5 µM decitabine, and/or 
100 nM TSA and/or 10 nM chaetocin (b) K562 cells were treated for 72 hours with 1 µM 
decitabine, and/or 500 nM TSA, and/or 50 nM chaetocin. Error bars represent standard deviation 
from three independent experiments.  D indicates Decitabine, T indicates TSA, C indicates 
Chaetocin. * indicates p <0.05, ** indicates p <0.005 relative to the control. 
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5.  DISCUSSION 
The aim of this study was to induce re-expression of a tumor suppressor gene, RIZ1, 
using epigenetic drugs.  Two model cell lines were used in the study, AML-193 (AML) and 
K562 (CML blast crisis).  RIZ1 was silenced in both of these cell lines, however they differed in 
methylation status, with AML-193 being completely methylated (94%) and K562 being hemi-
methylated (39%) (Figure 4.3).  Three epigenetic drugs were used: a DNA methylation inhibitor, 
decitabine, a histone deacetylation inhibitor, TSA, and an H3K9 methylation inhibitor, chaetocin.   
In order to effectively use these three drugs it was necessary to first determine their toxicity.  
Trypan blue and MTT assays were used to determine the toxicity of decitabine, TSA and 
chaetocin.  Treatment with decitabine caused a significant loss of viability, however this loss of 
viability was not enough to determine a reasonable median dose (Figure 4.4).  Clinical trials of 
decitabine are now concentrating on low dose schedules of the drug and it appears that lower 
doses enhance the ability of the drug to inhibit methylation of the DNA in patients as patients 
have shown a better response to lower doses of decitabine (Yang et al., 2006).  Therefore it 
seemed unreasonable to increase the dose further when lower doses have been shown to be more 
effective.  Cell cycle analysis was conducted on cells treated with decitabine and a G2 arrest was 
seen in both cell lines, along with an increase in the number of cells in the S phase (Figure 4.5).  
This indicated that although toxicity was low, there was a significant effect on the cell.  Both 
TSA and chaetocin caused significant loss of viability, enough for a median dose value to be 
determined (Figure 4.6, 4.7).   
DNA methylation is a common mechanism for silencing of tumor suppressor genes 
(Greger et al., 1989; Sakai et al., 1991).  DNA methylation in the RIZ1 promoter region has been 
observed in both AML and CML cell lines (Figure 4.3b).  Treatment with decitabine decreased 
the RIZ1 promoter region DNA methylation in both cell lines (Figure 4.11).  Interestingly, in 
AML-193 there were three CpGs which remained at 100% methylation, even upon treatment 
with 16 µM decitabine, suggesting that these CpGs have some protection from demethylation 
(Figure 4.12g). Currently the cause for this protection is unknown.   Most CpGs have similar 
losses of methylation within a few percentage points in AML-193 (Figure 4.12). In K562 cells 
the effects of decitabine were not universal, but instead certain CpGs experienced increases in 
methylation while others experienced decreases.  Treatment with 2 µM decitabine caused CpGs 
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1, 5, 9 and 15 to decrease in methylation by 4-9% while the 3’ most CpGs increased in 
methylation by 4% (Figure 4.13d).  The reasons for the different reactions to the treatments 
across the area analyzed and the difference between K562 and AML-193 are not yet known.  A 
possible reason may be that the two cell lines have a different reaction to decitabine treatment 
due to the differing levels of methylation between the two cell lines; K562 is only 39% 
methylated whereas AML-193 is 94% methylated.  Treatment with TSA had no effect on the 
methylation status of the RIZ1 promoter region in either cell line (Figure 4.14).   
Treatment with chaetocin caused an increase in promoter region DNA methylation in 
K562 (Figure 4.15b), and there was a slight pattern to the methylation changes seen (Figure 
4.16). Treatment with 20, 40, and 80 nM chaetocin had a global effect with the exception of a 
few CpGs outlined in the results section.  Interestingly, although treatment with chaetocin 
increased the amount of DNA methylation present, it was still able to induce RIZ1 expression  
(Figure 4.19a).  This suggested that DNA methylation is not the dominant event in 
transcriptional silencing.  Treatment with chaetocin had no effect on the methylation status of the 
RIZ1 promoter region in AML-193 (Figure 4.15a), yet RIZ1 expression was still induced. It is 
possible that because of the already high methylation levels in AML-193 that any increase in 
methylation would not be seen.  Evidence for this is seen when AML-193 is treated with 
decitabine and chaetocin together.  Cells treated with decitabine or decitabine plus TSA 
experienced a decrease in DNA methylation levels, however, treatment with chaetocin brought 
the methylation levels back up to near control levels (Figure 4.25a).  This was mirrored in K562 
where cells treated with decitabine or decitabine plus TSA experienced a drop in methylation and 
treatment with chaetocin increased the amount of methylation (Figure 4.25b).  One possibility as 
to why DNA methylation increased upon treatment with chaetocin is that the inhibition of 
SUV39h1 is increasing the levels or activity of the H3K9 dimethyltransferase G9a.  G9a 
stimulates DNMT1 activity, and so the increased presence of G9a would increase DNMT1 
activity and lead to higher RIZ1 promoter region DNA methylation levels (Esteve et al., 2006)  
Once the methylation profile had been established, the ability of these three drugs to 
induce RIZ1 expression was explored.  Both decitabine and chaetocin were able to induce RIZ1 
expression on their own (Figure 4.17, 4.19).  Decitabine is able to induce expression of tumor 
suppressor genes which have heavy promoter region DNA methylation (Constantinides et al., 
1977; Jones and Taylor, 1980), so it was expected that some induction would be seen by 
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decitabine.  Induction of a tumor suppressor by chaetocin is a novel finding, and the significance 
is increased as chaetocin did not reduce the amount of RIZ1 DNA promoter methylation.  This 
shows that demethylation of the RIZ1 promoter region DNA is not necessary to induce 
expression of RIZ1.   Although treatment with TSA alone had no effect on RIZ1 expression 
levels, TSA was able to potentiate the amount of induction seen by both decitabine and chaetocin 
(Figure 4.25).  Decitabine and chaetocin were also able to induce more RIZ1 expression together 
than each one alone (Figure 4.28).  This correlated with what was found when synergy and 
antagonism were investigated, whereby decitabine potentiated the effect of chaetocin in both cell 
lines and TSA in AML-193 (Table 4.1).  Treatment with all three drugs together induced RIZ1 
expression more than any drug treated alone, however there was less induction than treatment 
with any two drugs together.  In order to determine if there was any synergy between the drugs, a 
value called a combination index (CI) was determined.  Treatment with TSA and chaetocin 
induced a higher level of expression than each drug alone, however not as much as either 
decitabine plus TSA or decitabine plus chaetocin together (Figure 4.28).  This suggested that 
although demethylation of H3K9 is sufficient to induce expression, in order to achieve a high 
level of expression, DNA demethylation must occur. Treatment with all three drugs must affect 
the way the drugs are being taken up in the cell, distributed or secreted in some way that is 
different than when just two drugs are present, as there is similar induction when all three are 
treated together as treatment with decitabine plus TSA and decitabine plus chaetocin  (Figure 
4.28) (Hartshorn, 2006).   
Previous studies indicated that decitabine and TSA work synergistically (Kawamoto et 
al., 2008), however whether there was synergy between chaetocin and decitabine, and between 
chaetocin and TSA, were unknown.   In order to determine if there was any synergy between the 
drugs, a value called a combination index (CI) was determined.  The CI value is a value that 
measures the degree of synergism or antagonism between drugs.  In both cell lines at relevant 
ED values the CI value was less than 1.  This indicated that TSA and chaetocin acted 
synergistically. This was confirmed upon examining the amount of expression induced upon 
treatment of the cells with TSA and chaetocin (Figure 4.28).  In both cell lines there was a larger 
amount of RIZ1 expression when cells were treated with TSA and chaetocin together than when 
cells were treated with the drugs individually.   
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Since a median dose was not determined for decitabine, no claims of synergy or 
antagonism could be made. However, potentiation of  the effects of TSA and/or chaetocin by 
decitabine could be investigated.  In order to do this, the median doses of TSA and Chaetocin in 
the absence or presence of decitabine was examined.  In the presence of decitabine a drop in 
median dose values for both TSA and chaetocin was seen in AML-193.  This indicated that 
decitabine was potentiating the effect of TSA and chaetocin as it takes less of TSA or chaetocin 
in order to see the same effect (Table 4.1).  When examining RIZ1 expression, cells treated with 
decitabine plus TSA and decitabine plus chaetocin showed a larger induction of RIZ1 expression 
than cells treated with any drug alone (Figure 4.28).   
In all conditions examined, the addition of decitabine caused the CI values to increase, 
which indicated that decitabine interfered with the synergy between TSA and chaetocin.  This 
again correlates with the real time PCR data.  Although there was an increase in the amount of 
expression seen upon the addition of all three drugs together, it was less than any pair containing 
decitabine (Figure 4-28).  
From my data I conclude that through the use of three epigenetic drugs, it is possible to 
induce expression of RIZ1 in human CML and AML cell lines, and that treating cells with two 
drugs together worked better than one alone or when all three were present.  From the data 
presented here, a model was developed to explain what is occurring at the promoter during these 
events.   
Upon silencing, SUV39h1 is recruited to the histone, possibly by the Retinoblastoma 
protein, where it methylates the H3K9 residue (Nielsen et al., 2001).  The methylation of the 
H3K9 residue recruits HP1 to the site, which then recruits DNMT and HDACs to the silenced 
region, creating a complex that is able to effectively silence the gene (Wang et al, 2000).  This 
complex also likely contains MBD1 as it forms a complex with SUV39h1 (Fujita et al., 2003) 
(Figure 5.1).  Treatment with chaetocin induced RIZ1 expression even though the DNA 
methylation status of the promoter region remained unchanged, or the methylation increased.  
This suggested that H3K9 methylation is the dominant event in transcriptional silencing.  
Therefore, once SUV39h1 is inhibited by chaetocin, there is no methylation of the histone, and 
gene transcription can progress (Figure 5.1f, Figure 5.1g).   Treatment with decitabine also 
induces RIZ1 expression.  The demethylation of the DNA by RIZ1 caused MBD1 to release 
from the DNA, and the complex disassociated (Figure 5.1b, Figure 5.1c).  Once the complex is 
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disassociated, SUV39h1 can no longer methylate the H3K9 residue and transcription is able to 
start (Figure 5.1d).  
This model is important as it suggests how transcription begins and is aberrantly stopped.  
This model also allows for new pharmaceutical development into the targeting of this silencing 
complex.  Chaetocin was able to induce RIZ1 expression without affecting the methylation status 
of the RIZ1 promoter region DNA.  This suggests that DNA methylation is not the dominant 
event in transcriptional silencing, and that H3K9 methylation is the dominant event. From this 
data a model was developed to explain how the drugs are affecting the silencing complex present 
at the promoter region, and how treatment with either decitabine or chaetocin is able to induce 
expression.  Also, I determined that when cells are treated with decitabine, TSA and/or chaetocin 
in pairs there is a higher level of induction than any other treatment course studied.  Determining 
the dominance of epigenetic events in transcriptional silencing is important as pharmaceuticals 
can be targeted to the dominant events, thus increasing the effectiveness of cancer therapy.  Also, 
by determining whether pharmaceuticals targeted to certain epigenetic events are synergistic or 
antagonistic, it is possible to design treatment schedules to be more effective.   
 
5.1 Future Directions   
In order to test this model, chromatin immunoprecipitation (CHIP) experiments could be 
done to confirm the disassociation of SUV39h1 from the promoter region upon treatment of cells 
with decitabine and to assess the methylation status of the H3K9 residue upon this 
dissassociation.  Other tumor suppressor genes such as p15 or p21 could be studied to determine 
if this is a model specific to RIZ1 or if it is applicable to a wider set of genes.  The experiments 
conducted in this study could also be performed in patient material to confirm the results that 
were seen in cell lines are seen in actual cases of AML and CML.    
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Figure 5.1.  Model of Chromatin Remodelling During Drug Treatment.  (a,e)  Before treatment 
the histone is methylated on H3K9, promoter region DNA is methylated (circle on stick) and the 
complex is fully formed.  The gene is silenced (a) after decitabine treatment, (b) the DNA 
becomes demethylated, (c) the complex disassociates and, (d) upon SUV39h1 disassociating, the 
histone is no longer methylated and transcription can proceed.  After chaetocin treatment (f) the 
histone becomes demethylated and (g) transcription can proceed. 
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